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ABSTRACT 
Myocardial infarction (MI) is one of the most common causes of death in the 
world. The main symptom after the onset of MI is chest pain, which is one of the leading 
reasons for emergency department (ED) visits. When a patient arrives to the ED with chest 
pain, a rapid and accurate diagnosis is essential to immediately start the appropriate 
treatment. The measurement of cardiac biomarkers plays a key role in the diagnosis 
process, and improvements in this field could have a significant positive impact in the 
health of patients. Therefore, the development of fast, sensitive, and precise technologies 
to measure cardiac biomarkers is of great interest. 
This work focuses in the development of a surface enhanced Raman spectroscopy 
(SERS)-based assay to detect cardiac biomarkers. SERS is an attractive technique because 
it exhibits multiplexing and high sensitivity capabilities. Several SERS active 
nanoparticles were synthesized and functionalized with antibodies to use them in assays. 
They were characterized and compared to select the nanoprobe that exhibited stability, 
intense SERS signal, and functionality. In addition, various techniques to collect 
nanoparticles were examined. A device and method to consistently collect nanoparticles 
for SERS measurements was developed, which allowed to detect nanoprobe samples (10 
µL) across a range from nearly 27.4 fM to 1.7 pM with less than 10 % coefficient of 
variation (CV). Different assay formats were considered to implement the assay with the 
desired sensitivity and precision. After synthesizing the assay components, building the 
collection device, and selecting the sandwich assay format, an assay to detect cardiac 
troponin I (cTnI) was developed and tested. Various assay conditions were optimized to 
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improve the signal. Finally, a concentration curve that exhibited the expected response 
trend was obtained.    
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CHAPTER I  
INTRODUCTION 
I.1 Motivation and Significance   
According to the World Health Organization, cardiovascular disease (CVD) is the 
leading cause of death in the world. In 2012, an estimated 17.5 million people died from 
CVDs, representing 31% of all global deaths.1 Cardiovascular diseases are pathological 
conditions affecting the heart and blood vessels, such as: coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital 
heart disease, and deep vein thrombosis and pulmonary embolism.1 Among them, 
ischemic heart disease and stroke are the most prevalent. These diseases alone accounted 
for a combined 15 million deaths in 2015.2  
Symptoms of cardiovascular disease vary depending on the type of disease. For 
many people, chest pain or discomfort is the first sign.3 In a 2005 survey by the Centers 
for Disease Control and Prevention (CDC) 92% of the respondents recognized chest pain 
as a symptom of a heart attack.4 However, not all chest pain indicates the occurrence of a 
heart attack. Angina, or angina pectoris, is a common type of chest pain or a recurring 
discomfort that usually lasts a few minutes. This occurs when the heart muscle does not 
get enough blood supply or oxygen, which can happen during exercise or emotional stress 
when heart rate and blood pressure increase. As opposed to a heart attack, an angina attack 
does not permanently damages the heart muscle.5 In 2013, chest pain was the second 
leading reason for visiting the emergency department (ED).6 When a patients arrive at the 
ED, clinicians have the challenge to identify those who need to be admitted for urgent 
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management and those who can be discharged. If a patient has chest pain or related 
symptoms, the American Cardiology College/American Heart Association (ACC/AHA) 
guidelines recommend that physicians must perform a 12-lead ECG within 10 minutes of 
arrival to diagnose and treat myocardial infarction (MI).7-8 However, ECG is not a 
sensitive diagnosis and can be inconclusive even for a patient with MI.9-10 Approximately 
one quarter of the patients with chest pain in the ED present atypical symptoms and about 
one third have non-diagnostic cardiogram (ECG) changes.11 ECG is used to classify two 
different categories of acute coronary syndromes (ACS): ST-segment elevation 
myocardial infarction (STEMI) and ‘non-ST-segment elevation ACS’ (NSTEACS), 
which is further sub-divided into unstable angina and non-STEMI (NSTEMI).11 The 
treatment and intervention associated for each category is different; therefore, it is 
important to diagnose them accurately. Figure 1 shows some of the recommended 
guidelines to diagnose a patient with MI symptoms. 
 3 
 
 
Figure 1. Guidelines to diagnose a patient with MI symptoms. Diagnosis should be 
completed in less than 2 h to start treatment as soon as possible. Cardiac biomarkers 
diagnosis plays an important role in determining treatment.   
 
The lack of accurate diagnosis has negative consequences. About 5% of MI 
patients are incorrectly discharged from the emergency department.11 It has been reported 
that those patients have a risk adjusted mortality rate almost two times greater than that of 
hospitalized patients for ACS.12 In addition to adverse patient health outcomes, 
inadvertent discharge contributes to cases and payments of malpractice for ED physicians. 
Unintentional admissions and premature discharges also cause a significant financial 
burden.11-12 Patients awaiting the ruling out of NSTEMI represent the most frequent and 
time-consuming source of overcrowding in the ED. For these patients, the availability of 
sensitive and accurate point-of-care (POC) technologies to measure cardiac biomarkers in 
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addition to the common ECG recordings would have a considerable impact on the time 
spent under diagnostic evaluation.13  
No single diagnostic instrument can consistently detect and rule out the presence 
of an acute coronary syndrome at presentation to the ED.13 Therefore, multiple diagnostic 
approaches are usually used to stratify risks and decide the appropriate treatment.  Besides 
the common physical examination, assessment of medical history, and 12 lead ECG, 
additional methods for diagnosing MI include imaging and testing for cardiac biomarker 
levels. Imaging techniques such as X-ray, magnetic resonance imaging (MRI), or trans-
thoracic echocardiogram can help in the diagnosis process but are usually insufficient, 
expensive, or unavailable.14 As a result, the use of biomarkers such as troponin, 
myoglobin, and CK-MB has become a valuable tool to diagnose MI, apply the appropriate 
therapy strategy, and determine admissions and discharge decisions.11 Although the 
presence of a biomarker can confirm a diagnosis and speed care, the absence of it can also 
indicate physicians that they can perform additional tests, such as exercise stress testing, 
that cannot be accomplished safely until the patient has ruled out of NSTEMI.15   
Being able to diagnose patients with chest pain as early as possible is key because 
mortality caused by myocardial ischemia can be reduced significantly if definitive 
treatment is implemented rapidly16; however, this is not always possible in the ED due to 
uncertain ECG results and the time it takes to obtain blood test results.13, 17 Blood samples 
are taken from the patient at the moment of arrival and sent to the central laboratory for 
testing. The AHA/ACC guidelines suggest that laboratory results should be available 
within 60 minutes, preferably 30 minutes according to the National Academy of Clinical 
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Biochemistry (NACB), but in a number of institutions the central laboratory is unable to 
meet this requirement taking up to 71 minutes to provide results.7, 15, 17-18 Besides the 
approximate time required to perform some cardiac biomarkers assays (around 42 
minutes), collection and transport methods to the central laboratory usually take at least 
10 minutes, which contribute to the delay of the test results.18 
I.2 Background 
I.2.i Cardiac Biomarkers 
 Biochemical markers to diagnose acute myocardial infarctions (AMI) have been 
used for more than 50 years.19 Cardiac biomarkers are defined as biological analytes that 
can be detected in the blood at elevated levels after myocardial damage or during any 
cardiovascular disease.11 Currently, guidelines recommend the measurement of cardiac 
biomarkers in patients with suspected myocardial ischemia.12 It is also recommended that 
several measurements should be obtained depending on the initial results and the time they 
were collected. Cardiac biomarkers should be specific for cardiac tissue and accessible to 
attain high sensitivity measurements and thus predict cardiac injury.11 In addition, they 
need to be tested in clinical studies before they are accepted for clinical use. As 
technologies have advanced, different biomarkers have been discovered and monitored to 
diagnose AMI.19  
In the last years, the most routinely used biomarkers have been creatine kinase MB 
(CK-MB), myoglobin (MYO), and cardiac Troponin I (cTnI).10, 20 Cardiac troponin I is 
currently considered the gold standard or the biomarker of choice to diagnose AMI.10, 18 
However, one of the challenges of measuring only cTnI is its low concentration in the 
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blood at the first hours after an AMI onset, as can be observed in Figure 2. In contrast, 
higher levels of CK-MB and myoglobin can be detected moments after an AMI. The 
disadvantage of these biomarkers, especially myoglobin, is their low specificity to AMI, 
since their serum concentrations can increase in other clinical conditions other than 
AMI.10, 21 As a result, measuring multiple biomarkers simultaneously has been 
recommended by international associations.10 
 
Figure 2. Release time of common cardiac biomarkers. Myoglobin is released faster 
than troponin or CK-MB. Each biomarker reaches its peak at different times. Reprinted 
with permission from Wright et al.21 Copyright 2011 Wolters Kluwer Health, Inc. 
 
 Several assay technologies have been developed to simultaneously monitor cardiac 
troponin, CKMB, and myoglobin. A multimarker point-of-care (POC) test has been used 
in a 90 min protocol to diagnose AMI with good sensitivity and specificity (100% and 
94% respectively). Of the 90% of patients discharged with negative cardiac biomarkers 
results, only one returned with a MI within one month.22 Another study demonstrated that 
an assay technology that measures the three biomarkers allows rapid discharge of one-
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third of patients admitted with chest pain and only 1% readmission.23 Additional studies 
have also demonstrated benefit in using a multimarker approach to diagnose AMI.24-25 
However, studies have also shown that the measurement of myoglobin and CKMB, in 
addition to cTnI, does not add value to the diagnosis.26   
I.2.i.a Cardiac Troponin I  
 Currently, troponin is the most sensitive and specific biomarker of irreversible 
myocardia injury available in clinical settings.13 For this reason, cTnI is the most 
commonly used cardiac biomarker to detect AMI. This contractile protein is one of three 
sub-units (troponin C, troponin T, and troponin I) that compose the troponin complex of 
thin filaments of striated muscle.27 The complex is involved in the calcium sensitive switch 
that regulates the interaction of actin and myosin in striated muscle to control muscle 
contraction. Specifically, Troponin I binds to actin and inhibits actomyosin ATPase 
activity in the absence of calcium.28-29 It has a molecular mass of approximately 24 kDa 
and an isoelectric point (pI) of 9.9. 
  Troponin I has different isoforms expressed by different muscle tissues; however, 
cTnI is specific to the heart and is not expressed in normal skeletal muscle at any time.30 
The unique amino acid sequence of cTnI makes this protein an ideal biomarker for AMI 
and enables the development of monoclonal antibodies that do not cross react with skeletal 
troponins.31 Cardiac troponins are released over time when necrosis of the myocardium 
occurs. It has been reported that between 15-48% of patients with unstable angina have 
elevated levels of the biomarker.30 The concentration of cTnI in the blood increases about 
4-8 h following myocardial injury and peaks at 12-24 hrs.17, 32 The levels remain high for 
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at least 7 days.30 In first generations of cardiac troponins assays elevated levels were linked 
with secondary conditions such as renal failure, cardiomyopathy, and congestive heart 
failure among others. However, the specificity and analytical performance of current 
assays has improved significantly.11 The monitoring of cTnI levels has become an 
important information of the risk stratification process. It has been reported that patients 
who rule out for AMI, but who have high levels of troponins, have an outcome as poor as 
those who have had an AMI.30   
I.2.i.b Myoglobin  
 Myoglobin is a protein that contains iron and has a molecular mass of 18 kDa.33 It 
is very similar to hemoglobin, but only binds to one molecule of oxygen instead of four. 
Myoglobin takes up oxygen from hemoglobin and releases it for use into the mitochondria 
where oxidative reactions occur.33  
Myoglobin is a sensitive early biomarker of AMI. It has been monitored because 
its plasma levels can be raised as early as 1 h from onset of infarction, which doesn’t occur 
for other common cardiac biomarkers.19 It peaks between 6 to 9 h and can return to 
baseline in less than 24 h.34 The main disadvantage of using myoglobin as a cardiac 
biomarker is its low specificity. Myoglobin levels can be increased with several 
conditions, such as skeletal muscle disease or injury and renal impairment.19, 35 In addition, 
since the physiological concentrations of myoglobin that reflect skeletal muscle turnover 
depend on different factors such as muscular mass and sex, there are difficulties in 
establishing a decision limit.36 Furthermore, studies have demonstrated that high 
sensitivity troponin assays can have the same performance as myoglobin assays, making 
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the latter redundant.36-37 Nonetheless, myoglobin is still used to aid the diagnosis and 
stratification of cardiac injury early after symptom onset.35    
I.2.i.c Creatine Kinase MB  
 Creatine Kinase (CK) is a dimeric protein composed of two enzymatically active 
M (muscle-type) and B (brain-type) subunits with a molecular weight of 86 kDa.33, 38 CK 
catalyzes the transfer of phosphate from creatine phosphate to adenosine diphosphate to 
produce ATP, which is the energy source of most tissues.38 There are three dimeric 
isoenzymes of CK in human tissue: CK-MM, CK-MB, and CK-BB.39 CK-MB is almost 
exclusively found in the myocardium. It produces approximately 15% to 30% of the total 
CK activity per gram of myocardium.38 The other percentage (85% to 70%) is mostly 
produced by CK-MM.40 Ninety-nine percent of skeletal muscle is composed of CK-MM.40 
A small amount of CK-MB is present in skeletal muscle (less than 1% of the total).33 CK-
BB is found in brain tissue and is essentially absent from skeletal or cardiac tissue.38 
 Total serum CK levels are not specific to cardiac muscle damage.33 CK levels in 
serum can rise with increased muscle activity, stress, or trauma. It has been reported that 
CK serum levels of marathon runners were 21 times higher after the race and returned to 
baseline after 4 days.38, 40 In patients with AMI, the levels of total CK and CK-MB in the 
blood increase within the first 4-6 after the onset of symptoms.33 The levels peak at 18-24 
h and return to baseline values after 72 h.33 Since low levels of CK-MB are present in 
skeletal muscle, levels in the plasma can increase above the cutoff concentration indicative 
of AMI when skeletal muscle trauma occurs.33, 38 The relative index of CK-MB, which is 
CK-MB (in ng/mL)/total CK (in U/L), can be used to determine if elevations are due to 
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skeletal muscle damage. However, the relative index is useful only if patients have 
myocardial injury or skeletal muscle injury, but not if they have both. A study compared 
the relative index and absolute CK-MB concentrations and found that when the relative 
index is used the specificity increases, but the sensitivity is reduced.41 Therefore, it is not 
recommended to use the relative index or absolute CK-MB concentrations to diagnose 
myocardial damage when skeletal muscle disease is also present.33  
The recognition of the lack of specificity of CK-MB to diagnose AMI reinforced 
the search of cardiac biomarkers with superior performance.19 Reports found that cTnI 
tests exhibited similar detection limits than CK-MB but with substantially better 
specificity.31 In 2000, new guidelines changed the definition of AMI and suggested cardiac 
troponin as the preferred biomarker.42  
I.2.ii Diagnostic Requirements 
 Cutoff concentrations of some cardiac biomarkers, such as CKMB and myoglobin, 
are important to distinguish between AMI and non-AMI diseases, as some healthy subjects 
can have high concentrations of these markers due to skeletal muscle turnover. For cTnI, 
scientific international bodies (the European Society of Cardiology (ESC), the American 
College of Cardiology (ACC), the American Heart Association (AHA), and the National 
Academy of Clinical Biochemistry (NACB)) has recommended the use of a cutoff at the 
99th percentile of the normal range with a coefficient of variance (CV) of 10% or less. 
However, since most commercial assays do not meet this criteria, the current 
recommendation is to use the lowest troponin concentration obtained with at least 10% 
 11 
 
CV. In addition, it is recommended to measure the levels at different times after the first 
measurement (6 h and 12 h after measurement) to rule out AMI and 2-3 h to rule in AMI.33  
The National Academy of Clinical Biochemistry (NACB) recommends less than 
60 min (ideally 30 min) turnaround time (TAT) for troponin assays.18, 43 Another limitation 
of current cTnI assays is their low sensitivity at the time when the patient presents in the 
ED due to the delayed increase of the troponin circulating levels for 3 to 4 h and the need 
for serial sampling.44 The delay of plasma troponin levels is related to the time to develop 
cardiomyocyte necrosis and the time to develop irreversible injury of ischemic 
myocardium as a transmural wavefront.9, 45 In general, assays usually take 15 min or less; 
however, the time also depends in the number of biomarkers being measured.13  
In recent years, the improvement of available assays and the development of new 
assays have improved the precision at low concentrations of cardiac biomarkers such as 
cTnI.46-47 These high sensitivity assays are up to 50-fold more sensitive that currently used 
assays, and they can even detect troponin levels of healthy subjects.46 This enables for 
earlier and more sensitive detection of AMI.47 Figure 3 shows the different detection 
ranges of different generations of troponin assays. 
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Figure 3. Detection range of different generations of troponin assays. Immediately after 
onset of MI, troponin levels increase slightly and can only be detected by high sensitivity 
troponin assays. After a couple hours, troponin levels increase and can be detected by 
less sensitive assays. Reprinted with permission from Hochholzer et al.47 Copyright 2010 
Elsevier. 
 
Studies have demonstrated that using sensitive troponin assays can increase the 
diagnostic accuracy of AMI at initial presentation.48 However, when the established cutoff 
(99th percentile) is used, sometimes the diagnosis is not sensitive enough to make 
immediate clinical decisions, and additional measurements are needed after the initial 
measurement to follow the current guidelines.44, 49-50 Some studies suggest that serial 
testing after 3 h from presentation with AMI symptoms are not necessary if high sensitivity 
troponin assays are used.15 It has also been reported that using the lower detection limit of 
the high sensitivity cTnI assays at presentation as an alternative criteria to rule out AMI 
allowed for a more sensitive diagnosis that could enable physicians immediately exclude 
AMI in up to 27.7% of patients.49 Therefore, the use of high sensitivity troponin assays 
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can reduce the need of serial blood testing, which in turn can shorten the time for diagnosis 
and hospital discharge; in addition, it can also decrease the number of unnecessary 
hospitalization and the associated costs.44  
Assays for CK-MB should be able to detect concentrations below 1 ng/mL with a 
dynamic range of at least 100 ng/mL A precision of less than 10% CV at the cutoff 
concentration is desirable.33 A sensitivity of less than 5 ng/mL is desirable for myoglobin 
assays with a dynamic range of at least 500 ng/mL and a less than 10% CV at the cutoff 
concentration.33 Based on the performance information of several high sensitivity cTnI 
assays, the detection range goal of a cTnI assay should be approximately from 0.01 ng/mL 
to 1 ng/mL with 10% CV or less.51-52 
I.2.iii Current Cardiac Biomarkers Diagnostic Technologies 
Currently, there are several manufacturers of cTnI assays with different formats, 
antibodies, epitopes specificity, and detection techniques, such as fluorescent, 
chemiluminescent, electrochemical, or spectrophotometric. Each of them is vulnerable to 
interference from different variables such as haemolysis, icterus, lipaemia, anticoagulant, 
ascorbic acid, biotin, autoantibodies that can cause false positives and false negatives.19 
This also leads to differences in sensitivity, limits of detection (LOD), and values at which 
there is less than 10% coefficient of variation (CV).19 Since there is no standardization of 
cTnI measurements, each assay technology has its cutoff levels. Additionally, there is 
variation in the amount and type (blood, plasma, or serum) of measured sample used in 
the assays.13  
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There are currently few commercial high sensitivity cTnI assays (hs-cTnI) that 
meet the cutoff criteria of the 99th percentile of the normal range with less than 10% CV.9, 
52 However, assays with less than 20% CV at the 99th percentile can be used to make 
diagnosis and risk assessments.13, 33 Cardiac troponin I assays are available from many 
manufacturers; as opposed to the cardiac troponin T assays which is sold by only one 
manufacturer due to patent restrictions.33 Examples of current cTnI assay technologies 
with their corresponding CV% at the 99th percentile are shown in Table 1 and Table 2. As 
can be noted, most of the assays that have a CV of less than 10% at the 99th percentile are 
not FDA approved. The sensitivity and precision of POC assays is lower than the other 
technologies.  
 
Table 1. Overview of troponin assays. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cardiology 53, copyright 2017 
 
Company and platform 
or assay 
LoD 
(ng/L) 
99th percentile 
(ng/L) 
CV at the 99th 
percentile (%) 
FDA 
clearance 
Ortho Clinical Diagnostics 
hs-cT 
1 16-23 10 No 
Abbott Architect STAT hs-
cTnI 
1.1-1.9 16-34 <6 No 
Roche E 2010 / cobas e 411 / 
E 170 / cobas e 601 / 602 hs-
TnT (fifth-generation 
5 14-22 <8 Yes 
Ortho-Clinical Diagnostics 
VITROS Troponin I ES 
12 34 10 Yes 
Abbott Architect 12000 
STAT cTNI 
9 28 14 Yes 
Beckman Coulter 
AccuTNI+3 
10 20 14 Yes 
Abbott AxSYM ADV 20 34 14 Yes 
Siemens Dimension 
RXL TNI 
40 70 20 Yes 
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Table 2. POC troponin assays. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Cardiology 53, copyright 2017 
 
Company and 
platform or assay 
LoD 
(ng/L) 
99th percentile 
(ng/L) 
CV at the 99th 
percentile (%) 
FDA 
clearance 
LSI Medience 
PATHFAST cTnI 
1-8 20 5-28 Yes 
bioMerieux Vidas 10 10 27.7 Yes 
Alere Triage Cardio 3 10 12 NA No 
Philips MiniCare 18 43 18.6 No 
Abbott i-STAT 20 39 16.5 Yes 
 
I.2.iv Point of Care Assays 
 Point-of-care (POC) testing is defined as laboratory testing in or near the patient 
location.15 Advances in technology have permitted the development of POC assays that 
can be used in the ED. Since the average length of stay in the ED has been increasing 
particularly for patients from ethnic minorities, there is a clinical interest to reduce it.54 
The implementation of POC tests in medical centers has proven to be very advantageous. 
It has been demonstrated that POC tests can reduce the length of stay in the ED.19, 55 EDs 
that have employed POC testing identify it as necessary to achieve the recommended 
turnaround time (TAT) requirements.18, 56 When the worst TAT of the POC device (25 in) 
is compared to the worst TAT of the laboratory (92 min) an estimated annual bed-minutes 
savings of $1,209,600 can be calculated.18 In addition, it has been reported that the 
introduction of POC devices has reduced the charges to patients by 25%.57 POC devices, 
such as the i-Stat cTnI assay, have demonstrated good correlation compared to the core 
laboratory tests.9  
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The use POC devices has also increased the capacity of both the laboratory and 
ED without adding staff or equipment.18 Many POC devices are platforms utilized to 
perform multiple diagnostic tests by just changing the cartridge. This reduces the training 
requirements for the nursing staff because they only need to be trained to use the platform 
where several analytes are measured.  
 Although POC tests have many potential advantages, such as rapid diagnosis and 
increased flexibility, there are concerns about their accuracy.15 Currently, POC tests for 
cTnI are less sensitive than central laboratories tests, which could limit their use to rule 
out AMI.13 Studies that compared the results from POC devices and central laboratories 
using the same decision limits found that laboratory assays identified about 88% of all 
patients who died of CV disease during 35 months of follow-up compared with 54% for 
the POC assays.13 In addition, the lack of standardization has led to poor correlation and 
agreement between assays.19 The ideal POC test for diagnosis of AMI is not available 
yet;58 however, as new assays and technologies are developed, they will be able to meet 
the desired requirements.  
I.2.v Raman Spectroscopy 
Raman spectroscopy is a spectroscopic technique used to measure vibrational, 
rotational, and other low-frequency energy in a system 59. When light interacts with a 
molecule it can be absorbed or scattered. The scattered light can be classified as Rayleigh 
or Raman scattering.60 They are also known as elastic or inelastic scattering respectively. 
Rayleigh scattered light has the same frequency of the incident light. In contrast, in Raman 
scattering the photon exchanges energy with the analyte, which changes the energy of the 
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scattered photon. This energy interaction can be measured to obtain information about the 
vibrational modes of the molecule of interest.61 Raman scattering can also be categorized 
as Stokes scattering and anti-Stokes scatting (see Figure 4). In stokes scattering, the 
molecule is in its ground state when the photon interacts with it. At the interaction, energy 
is transferred to the molecule thus resulting in a higher vibrational energy level.62 
Alternatively, in anti-Stokes scattering, the molecule is already in an excited vibration 
level when the photon interacts with it. Therefore, energy is transferred from the molecule 
to the photon at the interaction, causing the molecule to lose energy and return to its ground 
state.62 The energy loss or gain during Raman scattering is related to the energies of the 
vibrational and rotational modes of a molecule.63 
 
Figure 4. Elastic and inelastic scattering. In Rayleigh scattering or elastic scattering no 
energy is transferred. Stokes scattering and anti-Stokes scattering are inelastic scattering. 
In inelastic scattering energy is exchanged. 
  
Raman spectral bands can be translated to the vibrational mode they represent.60 
To produce Raman scattering events, polarized monochromatic light is used to excite the 
molecule. This light distorts the electron cloud surrounding the molecule to an extent 
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dependent on the electrons ability to polarize. Polarizability is what causes the Raman 
scattering events.63 Therefore, vibration modes of molecules are Raman active if they 
cause a change in polarizability. The number of vibrational modes of a molecule is 3N-6 
for non-linear molecules and 3N-5 for linear molecules, where N is the number of atoms.64 
Examples of vibration modes are symmetric stretch, bending mode, and asymmetric 
stretch. Usually, symmetric vibrational modes cause the largest polarizability and produce 
the greatest scattering.63  
Raman scattering is expressed as the change in energy from the exciting radiation 
and its units are cm-1.63 The intensity of Raman scattering can be defined by using 
Equation 1, where K is the speed of light, l is the laser power, ω is the frequency of the 
incident radiation, and α is the polarizability of the electrons in the molecule. 
Equation 1 
I = Klα2ω4 
Raman spectroscopy is not efficient to detect analytes at trace levels due to the 
relatively low number of Raman scattered photons compared to the Rayleigh scattered 
ones. Approximately one in 106 - 108 photons is Raman scattered.63 Raman scattering is 
enhanced when small wavelength light is used. However, this light can also cause 
fluorescence, and broad fluorescent signals of higher intensity can overshadow the Raman 
signal.65 
I.2.vi Surface Enhanced Raman Spectroscopy (SERS) 
The Raman scattering signal can be greatly enhanced in the vicinity of metal 
structures such as gratings, island films or colloids 66. This enhancement scattering process 
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is referred as surface enhanced Raman spectroscopy (SERS). The enhancement can be 
explained by the electromagnetic and chemical mechanisms.  
 The electromagnetic mechanism explanation to SERS is based on the effect that 
surface plasmons of a metal have on the incident field intensity.67 Plasmons can be defined 
as a collection of free electron gas oscillating at the surface of a dielectric material, such 
as nanoparticles. Enhancements of less than 106 have been calculated for single 
nanoparticles.63 However, when metallic nanoparticles are collected or aggregated, they 
produce SERS hotspots which can cause greater enhancements, up to 1014.68 In this case, 
the increased electric field occurs at the interface between the nanoparticles. A simple 
description of the electromagnetic field can be explained with a model of a metallic sphere. 
When an electromagnetic field is applied to a nanoparticle with a laser, the field at the 
surface can be approximated with Equation 2. 
Equation 2 
Er = E0 cos θ + g (
a3
r3
) E0 cos θ 
In the expression, Er is the total electric field at a distance r from the sphere surface, a is 
the radius of the sphere, θ is the angle relative to the direction of the electric field, and g 
is a constant related to the dielectric constants (see Equation 3).  
Equation 3 
g = (
ε1(vL) − ε0
ε1(vL) + 2ε0
) 
In this equation, ε0 and ε1 are the dielectric constants of the medium surrounding the 
sphere and of the metal sphere respectively. The value vL is the frequency of the incident 
radiation.63 The value of g will be at a maximum when the denominator is at a minimum. 
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At the frequency when this occurs, the plasmon resonance frequency, the excitation of the 
surface plasmon increases the local field on the metal surface. The molecule adsorbed on 
the metal surface is then immersed in a freely moving electron cloud that intensifies the 
polarization of its surface electrons, which cause intense Raman scattering. As can be 
observed in Equation 2, the electric field is inversely proportional to r3. This means that 
the molecule has to be close to the metallic surface to experience the greatest electric 
field.63 The theoretical SERS enhancement factor is the fourth power of the 
electromagnetic field enhancement at the nanoparticle surface or E4.69 
 Another theory that explains the SERS enhancement is the chemical mechanism. 
Chemical enhancement occurs when a bond between a molecule and a nanoparticle 
exists.63 This bond allows the transfer of charge from the metal surface to the molecule. 
In this mechanism, electrons or holes can travel to the metal-molecule bond, interact with 
the molecule causing an increase in the polarizability, and return back to the metal 
surface.63 For chemical enhancement to occur, the molecule has to be attached to the 
nanoparticle surface. Although, evidence suggests that both the electromagnetic and 
chemical enhancement occur, it is believed that electromagnetic enhancement has a 
greater effect.63  
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CHAPTER II 
FUNCTIONALIZATION OF SERS ACTIVE NANOPARTICLES 
II.1 Introduction to Nanoparticle Functionalization 
 Nanoparticles are particles with a diameter from 1 to 100 nm.70 There are many 
types of nanoparticles composed of different materials. Among them, gold and silver are 
the most common and investigated.70 Nanoparticles have unique properties, such as 
biocompatibility, optical, and electronic properties, that make them useful for many 
applications, including biosensing applications.71 Specifically, nanoparticles have high 
surface-to-volume ratio and high surface energy that can help to immobilize biomolecules 
on them. Some nanoparticles, such as gold NPs, can allow fast and direct electron transfer 
between electroactive species and electrode materials. Moreover, they have light-
scattering properties and a local electromagnetic field that allows them to be used as signal 
amplification labels in different sensors, such as SERS based sensors.72 Some 
nanoparticles can also exhibit magnetic behaviors that can be used to separate or 
concentrate them in a solution.71  
 Nanoparticles synthesis techniques have been continuously evolving, leading to 
improvements that have allowed to control their size, shape, and morphology.70 The ability 
to manipulate these parameters permits to optimize them in order to meet their application 
requirements. In addition, the surface and core of the nanoparticles can be modified for 
                                                 
 Part of this chapter is reprinted with permission from Garza, J. T.; Cote, G. L. In Design of Raman active 
nanoparticles for SERS-based detection, Proc. of SPIE Vol, 2016; pp 97221B-1. Copyright 2016 Society 
of Photo Optical Instrumentation Engineers 
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specific purposes such as bio-recognition, chemical sensing, drug delivery, therapeutics, 
and imaging.70-71 Interest in this field has made the development of new protocols to 
control nanoparticles and make them functional an active research area.70  
 Nanoparticles have been used in numerous assays. They can be conjugated with 
antibodies, proteins, aptamers, DNA, or many other compounds to be utilized in 
colorimetric, fluorescent, SPR, ELISA, SERS, and electrochemical based sensors. Several 
reviews discuss the use of nanoparticles in biosensors.70-71, 73-74    
II.1.i SERS Active Nanoparticles 
In order to obtain a SERS signal, a substrate that enhances the spectrum of a Raman 
active molecule is needed. Numerous SERS substrates have been synthesized to produce 
high signal enhancement and thus create more sensitive assays. Examples of substrates 
are silver or gold nanoparticles75-76, nanocubes77, nanostars78,  nanorods79, and other 
structures.80 The morphology of these metallic structures can affect the degree of 
enhancement. Therefore, when the appropriate excitation laser wavelength is used, some 
substrates are affected more than others. Another way to increase the SERS enhancement 
is by aggregating the metallic substrates to create hot spots between them. Hot spots are 
confined regions of intense local field enhancement produced by surface plasmon 
resonances that usually occur between junctions of metallic structures.81 Clusters of 
nanoparticles have been used as SERS substrates, and in order to protect and stabilize the 
aggregated nanoparticles functionalized with Raman reporter molecules (RRM), they 
have been encapsulated in silica.82-83 These silica encapsulated aggregates can also be 
functionalized with biomolecules to create nanoprobes that can be used in assays.84 
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II.2 Nanoparticles and Bioconjugation Approaches Tested 
 Different nanoparticles were synthesized to functionalize them and analyze their 
potential use as assay components. Also, several conjugation approaches were explored 
to determine the one with best performance according to the selected factors of interest. 
The stability of the functionalized nanoparticles, the SERS intensity, and the successful 
conjugation of proteins on the nanoparticles were defined as the factors to be analyzed for 
each approach. The nanostructures that were synthesized included gold (Au) and silver 
(Ag) nanoparticles. A Raman reporter molecule was conjugated to make them SERS 
active, and various PEG linkers were used to conjugate cardiac Troponin I. 
II.2.i Materials and Methods 
II.2.i.a Materials  
Cardiac Troponin I (cTnI) was purchased from GenScript (NJ, USA). Hetero 
bifunctional silane-PEG-NHS (5 kDa) and thiol-PEG-NHS (3 kDa) linkers were bought 
from NanoCS (NY, USA). EDC-HCl and sulfo-NHS were acquired from CovaChem (IL, 
USA). CA-PEG (441.5 Da) and NHS-PEG-NHS (532.5 Da) linkers were purchased from 
Thermo Fisher Scientific (MA, USA). Gold chloride trihydrate (HAuCl4), sodium citrate 
tribasic dihydrate, hydroxylamine hydrochloride, sodium hydroxide, silver nitrate, 
tetraethyl orthosilicate (TEOS), (3-Aminopropyl)trimethoxysilane (APTMS), ammonium 
hydroxide (28%), TRIS base, HEPES, 5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB), 
sodium chloride (NaCl), ethanol, and isopropanol (IPA) were obtained from Sigma 
Aldrich (MO, USA).  
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II.2.i.b Measurements Methods  
Absorbance measurements were acquired on a Tecan microplate reader. TEM 
images were collected on a FEI Morgagni TEM. A Thermo Scientific DXR Raman 
confocal microscope with a 780 nm or 532 nm laser was used to measure the SERS signal. 
The laser power used was varied in different experiments. 
II.2.i.c Gold Colloid Synthesis  
 Gold nanoparticles were synthesized based on the method described by Bastus85 
and modified by You86. In summary, 335 µL of 25 mM HAuCl4 was added to a 200 mL 
round bottom three neck flask with 50 mL of boiling 2.2 mM sodium citrate solution. The 
mixture was stirred and boiled under reflux for 10 min. As the Au NP seeds were formed 
the color of the solution turned red. The seed solution was cooled to 90° C. Then, 335 µL 
of 60 mM sodium citrate was added. After 2 min, 335 µL of 25 mM aqueous HAuCl4 was 
also added. The mixture was left stirring at 90° C for 30 min under reflux.  
II.2.i.d Silver Colloid Synthesis 
Silver nanoparticles were synthesized based on the method described by Leopold 
and Lendl.75 Briefly, 1 mL of hydroxylamine hydrochloride (1.50 x 10-1 M) was mixed 
with 89 mL of sodium hydroxide (3.33 x 10-3 M) under vigorous stirring. Silver nitrate 
solution (10 mL, 1 x 10-2 M) was added drop-wise to the stirring solution. The solution 
was left stirring for 15 min at room temperature. This nanoparticle solution was then used 
for the functionalization procedures moving forward as described below. 
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II.2.ii Au-RRM-Antigen 
 The RRM used to make the nanoparticles SERS active is DTNB. DTNB is a 
molecule that contains a thiol group that binds to gold or silver to form a self-assembled 
monolayer (SAM) on the surface of the nanoparticles. This molecule also contains a nitro 
and a carboxyl group. In this conjugation strategy, EDC/NHS chemistry was used to 
conjugate Troponin I by forming a bond between the carboxyl group of the DTNB and an 
amine group present in the protein. 
II.2.ii.a Protocol 
 To conjugate the proteins 100 µL of 10 mM of DTNB in ethanol was added to 6 
mL of Au nanoparticles and incubated overnight. The nanoparticles solution was 
centrifuged (2000 g, 15 min), redispersed in 2 mL of HEPES (pH 6), and sonicated. Then, 
10 µL of EDC (0.019 mM) and 10 µL of Sulfo-NHS (0.047 mM) were mixed and 
incubated at room temperature for 15 min. The solution was centrifuged, redispersed in 2 
mL of HEPES (pH 7.2), and sonicated. After that, 67 µL of the protein solution (672.6 
ng/mL) was mixed and incubated for 2 hrs. Finally, the reaction was quenched with 50 
mM TRIS, and the nanoparticles solution was washed and redispersed in 2 mL of HEPES 
(pH 7.2).  Figure 5 shows the conjugation schematic.  
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Figure 5. Au-RRM-Antigen conjugation strategy. EDC and sulfo-NHS are used to 
conjugate cTnI to DTNB, which is attached to the Au nanoparticle. 
 
II.2.ii.b Characterization 
 The extinction spectrum of the nanoparticles at each stage of the functionalization 
process (Au nanoparticles, Au nanoparticles functionalized with DTNB, and Au 
nanoparticles functionalized with DTNB and troponin I) was measured to examine the 
degree of aggregation. As can be observed in Figure 6, the Au nanoparticles functionalized 
with protein exhibit increasing values at high wavelengths. This indicates uncontrolled 
aggregation as red shifts or increasing extinction values at high wavelengths occur when 
nanoparticles aggregate. In addition, aggregation was observed by visual inspection. 
 27 
 
 
Figure 6. Extinction spectrum at different steps of the functionalization process of Au-
RRM-Antigen. 
 
 A higher amount of troponin I could have been conjugated to prevent instability. 
In addition, a hydrophilic linker or other stabilizing proteins, such as BSA, could have 
been introduced to improve stability and prevent aggregation.  
II.2.iii Au-RRM-CAPEG-Antigen 
 In this conjugation strategy, a hydrophilic PEG linker was used to attach cTnI to 
the Au nanoparticles functionalized with the reporter molecule DTNB. The 441.5 Da PEG 
linker (CA-PEG) consisted of an amine functional group in one side and a carboxyl group 
on the other side. In this case, EDC/Sulfo-NHS chemistry was used to conjugate the 
carboxyl group of the DTNB molecule with the amine group of the PEG linker. Then, the 
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cTnI protein was attached to the carboxyl end group of the PEG linker with the same 
conjugation chemistry.  
II.2.iii.a Protocol 
 For the conjugation, 100 µL of 10 mM of DTNB in ethanol was added to 6 mL of 
Au nanoparticles and incubated overnight. The nanoparticles were washed by 
centrifugation and redispersion in 2 mL of HEPES (pH 6). Then, 10 µL of EDC (2 mM) 
and 30 µL of Sulfo-NHS (1.7 mM) were added and incubated at room temperature for 15 
min. After washing them and redispersing them in HEPES (pH 7.2), 10 µL of the CA-
PEG solution (0.45 mM) was added and incubated for 2 hrs. The free NHS groups were 
quenched with TRIS, and the nanoparticles were washed three times and redispersed in 
HEPES (pH 6). EDC (10 µL, 0.019 mM) and Sulfo-NHS (10 µL, 0.047 mM) were added 
again for the conjugation of the carboxyl groups of the linker with the amine groups of the 
proteins. Following the EDC and Sulfo-NHS mixing with the nanoparticles, the solution 
was incubated for 15 min, washed, and 67 µL of protein solution (672.6 ng/mL) was 
added. After 2 hrs of incubation, the nanoparticles were washed and redispersed in HEPES 
(pH 7.2). Figure 7 shows the schematic of the conjugation strategy. 
 
Figure 7. Au-RRM-CAPEG-Antigen conjugation strategy. EDC and sulfo-NHS are 
used to attach DTNB to a PEG linker and the linker to cTnI. 
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II.2.iii.b Characterization 
The extinction spectrum was also measured at different stages of the 
functionalization process to analyze how the original plasmon peak of the gold 
nanoparticles changes as the protein is conjugated. Figure 8 shows the recorded extinction 
spectra. As can be observed, this conjugation approach also causes an increase in 
extinction values at higher wavelengths when protein is attached, which indicates 
aggregation of the nanoparticles. 
 
Figure 8. Extinction spectrum at different steps of the functionalization process of Au-
RRM-CAPEG-Antigen. 
 
 For the described protocol, the addition of the hydrophilic PEG linker did not 
improve the stability of the nanoparticles to prevent aggregation. However, the 
optimization of different factors, such as the amount and ratios of RRM, PEG linker, and 
cTnI protein used could improve the stability of the nanoparticles to prevent aggregation.    
 30 
 
II.2.iv Au-RRM-PEG-Antigen 
 Another functionalization approach was tested in which the RRM and a PEG linker 
were also used. However, in this case the PEG linker was not attached to the DTNB 
molecule. In this functionalization strategy, a thiol-PEG-NHS linker was used to conjugate 
it with the Au nanoparticles directly through the thiol-Au reaction. Then, the cTnI protein 
was conjugated through the reaction of the amines present in the protein with the NHS of 
the linker. 
II.2.iv.a Protocol  
To functionalize the Au nanoparticles 21.4 µL of the thiol-PEG-NHS linker (0.6 
mM) and 40 µL of DTNB in ethanol (10 mM) were mixed with 1 mL of nanoparticles. 
The solution was vortexed, and citrate buffer (60 µL, 250 mM) was also added to improve 
the conjugation efficiency. After 30 minutes, the nanoparticles solution was centrifuged 
and redispersed in 100 µL of HEPES (pH 7.5). Subsequently, 100 µL of cTnI (10 µg/mL) 
and 10 µL of CAPEG linker (0.12 mM) were added to react with all the free NHS groups. 
The solution was incubated for 30 min, washed two times and redispersed in HEPES 
buffer. Figure 9 demonstrates the conjugation strategy. 
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Figure 9. Au-RRM-PEG-Antigen conjugation strategy. DTNB and a PEG linker attach 
to the Au nanoparticle through their thiol group. Then, cTnI is attached to the linker.  
 
II.2.iv.b Characterization  
The extinction spectrum of the nanoparticles was measured before and after the 
conjugation of the PEG linker and protein, as can be observed in Figure 10. In this case, 
both spectra had the same shape, and the spectrum of the functionalized nanoparticles did 
not exhibit an increase in extinction values at higher wavelengths. This suggests that the 
nanoparticles did not aggregate after conjugating cTnI. Nevertheless, after 
functionalization, the nanoparticles were sticking to the walls of the microtube (inset of 
Figure 10). The loss of nanoparticles due to washing steps and sticking to the wall caused 
a decrease in nanoparticle concentration, which subsequently resulted in a spectrum of 
lower extinction values than the spectrum of the Au nanoparticles stock solution. 
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Figure 10. Extinction spectrum at different steps of the functionalization process of Au-
RRM-PEG-Antigen. Inset: Nanoparticles sticking to the walls of the microtube. 
 
 The nanoparticles sticking to the wall of the microtube could have been caused by 
the hydrophobic nature of the cTnI protein attached.87 The addition of BSA or Tween 20 
could have been used to reduce nonspecific binding and improve the stability of the 
nanoparticles. 
II.2.v Au-RRM-Silica-PEG-Antigen 
 An alternative functionalization approach was tested to make the nanoparticles 
SERS active and attach the protein of interest. In this case, the RRM formed a SAM around 
the nanoparticles to cover them completely. Then, the nanoparticles functionalized with 
DTNB were aggregated and encapsulated in silica. An NHS-PEG-NHS linker was used 
to conjugate the cTnI protein to the silica nanoparticles.  
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II.2.v.a Protocol 
 Specifically, 50 µL of DTNB in ethanol (10 mM) was mixed with 1 mL of Au 
nanoparticles and incubated overnight. Then, the nanoparticles were washed two times 
and redispersed in 2 mL of ethanol. APTMS (10 µL, 0.001% in ethanol) was added and 
incubated for 10 min to form a thin layer of silica around the nanoparticles. The 
nanoparticles were washed and redispersed in 1000 µL IPA, 360 µL DI water, and 24 µL 
ammonium hydroxide (28%). After sonication, 10 µL of TEOS (1% in IPA) was added 
three times in an interval of one hour under stirring. The nanoparticles solution was 
incubated overnight under stirring, washed the next day, and redispersed in 2 mL of 
ethanol. Subsequently, 5 µL of APTMS (0.001% in ethanol) was added and incubated for 
30 min to introduce amine groups on the surface of the silica nanoparticles. The 
nanoparticles were washed two times, and redispersed in 2 mL of ethanol. Then, 5 µL of 
the NHS-PEG-NHS linker (90 mM) was added and incubated for 30 min. The solution 
was washed two times and redispersed in HEPES buffer. The protein cTnI (45 µL, 30 nM) 
was introduced for conjugation, incubated for 30 min, quenched with TRIS buffer (1 M) 
and washed to redisperse it in 2 mL of HEPES. Figure 11 shows the conjugation 
schematic.  
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Figure 11. Au-RRM-Silica-PEG-Antigen conjugation strategy. Au nanoparticles are 
functionalized with DTNB, aggregated, and encapsulated in silica. An NHS-PEG-NHS 
linker is then used to conjugate cTnI to the silica surface through their amine groups.  
 
II.2.v.b Characterization  
The extinction spectrum at different stages of the functionalization process was 
measured to analyze the aggregation and stability of the nanoparticles. In this case, as can 
be observed in Figure 12, the aggregation of the nanoparticles encapsulated in silica 
resulted in an extinction spectrum with two localized surface plasmon resonance (LSPR) 
peaks. This occurred because the LSPR peaks are related to the interparticle gap distance, 
which changes as the nanoparticles aggregate. A main advantage of this conjugation 
method is the protection that the silica shell provides to the functionalized nanoparticles. 
In addition of preventing the binding of molecules other than the RRMs, the silica shell 
immobilizes the controlled aggregates. The silica surface also provides flexibility for 
further conjugation methods since it can be treated to add the desired functional groups.  
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Figure 12. Extinction spectrum at different steps of the functionalization process of Au-
RRM-Silica-PEG-Antigen. The second peak indicates controlled aggregation. 
  
 Even though the nanoparticles were aggregated in a relatively controlled manner 
inside the silica shell, the silica encapsulated nanoparticles functionalized with cTnI were 
not very stable. A couple hours after functionalization, they tended to agglomerate and it 
was difficult to redisperse them. The addition of BSA or Tween 20 could have improved 
the stability of the nanoparticles by blocking free spaces and preventing non-specific 
binding.   
II.2.vi Nanoparticles SERS Intensity Comparison 
 The SERS spectra of the stock solutions of the Au nanoparticles functionalized 
with different methods were measured and compared. Factors that can affect the SERS 
intensity of SERS active substrate solution include: type of substrate, concentration, 
 36 
 
degree of aggregation, and amount of RRM on the substrate. In Figure 13 the intensities 
of the spectra can be compared. As can be observed, the spectrum of the silica 
encapsulated nanoparticles exhibited the highest intensity. This occurred because the 
nanoparticles were aggregated inside the silica, and hotspots or regions of intense local 
field enhancement were created between the junctions of the metallic nanoparticles. The 
SERS signal increases with increasing number of hotspots. The nanoparticles 
functionalized with methods that indicated aggregation in their extinction spectra (two 
approaches in which the antigen was attached to the RRM) had lower SERS intensity than 
the silica encapsulated nanoparticles but higher intensity than the method which did not 
indicate aggregation in its extinction spectrum (approach in which thiol-PEG-NHS linker 
was used). The lack of aggregation and the lower amount of RRM on each nanoparticle 
prevented the method with the lowest intensity (Au-RRM-PEG-Antigen) to have high 
SERS intensity.  
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Figure 13. SERS signal of Au nanoparticles functionalized with cTnI by using different 
strategies. Au-RRM-Silica-PEG-Antigen exhibited the greatest SERS signal. 
 
The volume used to measure the SERS spectra was 30 µL. However, it is important 
to note that the concentrations of the stock solutions were different. The stability of the 
functionalized nanoparticles caused some particles to stick to the wall; as a result, 
nanoparticles were lost and the concentrations decreased for some approaches. Even 
though the concentrations were not the same for the functionalization approaches, the 
analysis provided useful information. The comparison of the extinction spectra, the visible 
inspection of aggregates in solution, and the SERS spectra of the different Au 
nanoparticles allowed to identify the approach that exhibited higher stability when a 
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protein was conjugated and estimate the one that produces higher SERS intensity, which 
was the silica encapsulated nanoparticles.  
II.2.vii Ag-RRM-Silica-PEG-Antigen 
 Silver nanoparticles were synthesized to test them as SERS substrate and 
determine if they induce a greater enhancement than gold. The functionalization approach 
that resulted in the highest SERS signal when the different methods were compared was 
used to functionalize the Ag nanoparticles. Ag nanoparticles were encapsulated in silica, 
conjugated with cTnI, and characterized. The SERS signal obtained when Ag 
nanoparticles were used was compared to the signal obtained with Au nanoparticles. 
 The functionalization protocol was very similar to the protocol of the silica 
encapsulated Au nanoparticles described before. However, in this case Ag nanoparticles 
were used and more protein was conjugated. Figure 14 shows the functionalization 
strategy of the Ag nanoparticles. 
 
Figure 14. Ag-RRM-Silica-PEG-Antigen functionalization strategy. Ag nanoparticles 
are functionalized with DTNB, aggregated, and encapsulated in silica. Then, an NHS-
PEG-NHS linker is used to conjugate cTnI to the silica surface through their amine 
groups. 
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 TEM images of the nanoparticles were taken to inspect their morphology and the 
silica encapsulation. As can be observed in Figure 15, the Ag nanoparticles were 
successfully encapsulated in silica, which can be noticed around them. The number of 
nanoparticles aggregated inside the silica shell was not very consistent. Monomers, 
dimers, trimers, tetramers, and larger aggregates were formed in the same batch. 
 
Figure 15. TEM images of Ag nanoparticles encapsulated in silica. 
 
 The extinction spectrum of the nanoparticles was measured before and after 
encapsulation. The plasmon peak of the Ag nanoparticles was around 410 nm, as can be 
seen in Figure 16. After encapsulation, it the extinction spectrum changed, similar to the 
Au nanoparticles case, to show a second plasmon peak. The second peak indicated that 
the nanoparticles were aggregated. The size of the nanoparticles was also measured with 
a Nanosight NTA (Malvern) instrument, and the mean size was determined to be 62 nm 
for the Ag nanoparticles and 117 nm after they were encapsulated.  
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Figure 16. Extinction spectrum of Ag and Ag-RRM-Silica. The second peak of the Ag-
RRM-Silica spectrum (at approximately 670 nm) indicates controlled aggregation.  
 
The SERS spectrum of Ag functionalized nanoparticles was measured to compare 
it to the spectrum of Au functionalized nanoparticles. A 780 nm laser (5 mW) was used to 
take the measurements, and the same volume of similar concentrations of nanoparticles 
(4.7 x 10-11 M for 40 nm silver nanoparticles and 3.7 x 10-11 M for 60 nm gold 
nanoparticles) was tested. Figure 17 shows the SERS spectra obtained for the two types 
of nanoparticles used. As can be noted, using Ag nanoparticles resulted in greater SERS 
signal, about 7 times higher intensity than the Au nanoparticles at 1338 cm-1. This result 
suggests that higher intensities will be obtained at low concentrations if Ag nanoparticles 
are used, which is desirable for the design of SERS based biosensors that require high 
sensitivity and low limits of detection.   
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Figure 17. SERS signal comparison between functionalized Au and Ag nanoparticles. 
The use of Ag nanoparticles produced the greatest SERS signal.  
 
II.3 SERS Nanoprobe 
 After testing different methods of functionalizing nanoparticles to make them 
stable and SERS active, the approach in which Ag nanoparticles were encapsulated in 
silica was selected. This functionalization method produced stable nanoparticles with high 
SERS intensity and the ability to be conjugated with the proteins of interest. In this case, 
cTnI was conjugated to silica encapsulated Ag nanoparticles, which can be referred as 
nanoprobes, to analyze if they could be used in assays. 
 The first versions of the nanoprobe employed the NHS-PEG-NHS linker to attach 
proteins on the amine active surface of the silica nanoparticles. However, this method 
resulted in agglomeration of nanoparticles when the functional groups of a linker reacted 
with amine groups of different nanoparticles. The linker had to be added in excess to 
 42 
 
prevent this from happening. To have more control of the amount of linker conjugated on 
each nanoparticle and avoid crosslinking, the linker silane-PEG-NHS was utilized. The 
surface of the silica nanoparticles did not have to be amine modified to use this linker, 
which was another advantage since it increased the stability of the nanoparticles. Figure 
18 shows the nanoprobe functionalization strategy.  
 
Figure 18. Nanoprobe functionalization strategy. Ag nanoparticles were functionalized 
with DTNB, aggregated, and encapsulated in silica. A silane-PEG-NHS linker was used 
to attach cTnI to the silica surface.   
 
II.3.i Materials and Methods 
II.3.i.a Materials 
Cardiac Troponin I (cTnI) was purchased from GenScript (NJ, USA). Hetero 
bifunctional 5 kDa PEG linker (Silane-PEG-NHS) was bought from NanoCS (NY, USA). 
The troponin I (human cardiac specific) enzyme immunoassay test kit was obtained from 
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GenWay (CA, USA). Hydroxylamine hydrochloride, sodium hydroxide, silver nitrate, 
tetraethyl orthosilicate (TEOS), (3-Aminopropyl)trimethoxysilane (APTMS), ammonium 
hydroxide (28%), gold(III) chloride trihydrate (HAuCl4), Bovine Serum Albumin (BSA), 
TRIS base, Tween 20, 5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB), sodium chloride 
(NaCl), sodium phosphate, glycerol, ethanol, and isopropanol (IPA) were obtained from 
Sigma Aldrich (MO, USA).  
The size and concentration was measured with a Nanosight NTA (Malvern). The 
zeta potential was measured on a Zetasizer Nano (Malvern). Absorbance measurements 
were acquired on a Tecan microplate reader. TEM images were collected on a FEI 
Morgagni TEM and SEM images on a JEOL JSM-7500F. A Thermo Scientific DXR 
Raman confocal microscope with a 532 nm laser was used to measure the SERS signal. 
Samples were excited with 2 mW, an exposure time of 1 s, and 5 exposures per reading. 
The estimated wavenumber resolution was approximately 5.4 cm-1 FWHM. 
II.3.i.b Colloid Synthesis 
As described earlier, silver nanoparticles were synthesized based on the method 
described by Leopold and Lendl.75 Briefly, 1 mL of hydroxylamine hydrochloride (1.50 x 
10-1 M) was mixed with 89 mL of sodium hydroxide (3.33 x 10-3 M) under vigorous 
stirring. Silver nitrate solution (10 mL, 1 x 10-2 M) was added drop-wise to the stirring 
solution. The solution was left stirring for 15 min at room temperature. This nanoparticle 
solution was then used for the functionalization procedures moving forward as described 
below. 
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II.3.i.c Silica Encapsulation 
The procedure to encapsulate the nanoparticles was based on the method described 
by Schütz.88 First, DTNB (250 µL, 1 x 10-2 M) was added to 5 mL of the synthesized silver 
nanoparticles to form a self-assembled monolayer (SAM) on the nanoparticles. After 
overnight incubation at room temperature, the nanoparticles were separated into five 
microtubes of equal volumes, centrifuged (2700 g, 15 min), redispersed in ethanol (900 
µL) and water (65 µL), and combined in a single tube. In order to aggregate the 
nanoparticles and form hotspots, NaCl solution was added (175 µL, 2 x 10-2 M), incubated 
for 30 min, and sonicated. Subsequently, 50 µL of APTMS (0.001% in ethanol) was added 
to the nanoparticles and incubated for 10 min. After incubation, the nanoparticles were 
separated into five microtubes, centrifuged, redispersed in a mixture of IPA (1000 µL), DI 
water (360 µL), and ammonium hydroxide (25 µL, 28%), sonicated for 10 min, and 
combined in a single tube. Then, 50 µL of TEOS (1% in IPA) was added, and the sample 
was placed on a stirring rotator. After 30 min, an additional 25 µL of TEOS was added. 
The nanoparticles solution was left reacting overnight at room temperature in the rotator. 
Afterwards, they were centrifuged and redispersed in 1 mL of ethanol. Figure 19 shows 
the nanoprobe synthesis approach. 
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Figure 19. Nanoprobe synthesis stages. Ag nanoparticles are created. DTNB was added 
to form a SAM on the nanoparticles. The nanoparticles were aggregated and 
encapsulated in silica. After silica encapsulation, a silane-PEG-NHS linker is used to 
conjugate cTnI and BSA with nanoclusters. 
 
II.3.i.d Differential Centrifugation 
To decrease the polydispersity of the silica encapsulated nanoparticles, they were 
separated with a continuous density gradient centrifugation method described by 
Steinigeweg.89 In brief, five different glycerol-water mixtures were prepared (30, 35, 40, 
45, and 50 vol % glycerol). After preparation, 2 mL of each solution was stacked carefully 
on top of each other with a syringe starting with the 50 % mixture at the bottom of a 15 
mL tube. After stacking all the mixtures, the tube was gently tilted horizontally for 5 min 
to form a continuous gradient and centrifuged at 2500 g for another 5 min. The silica 
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encapsulated nanoparticle solution (300 µL) was added on top of the gradient and 
centrifuged at 2500 g for 45 min. After centrifugation, the gradient solution was separated 
in sections by extracting about 2 mL for each section. The nanoparticles in each section 
were washed three times and redispersed in ethanol (200 µL). Two more gradients were 
used to separate 600 µL of the silica nanoparticles solution. After washing all the sections, 
the size of the silica encapsulated nanoparticles in each section was measured with the 
NTA. The sections with nanoparticles of similar size (89 - 90 nm) were combined to form 
the solution used for further functionalization. 
II.3.i.e Preparation of BSA with Nanoclusters 
BSA nanoclusters were made based on the method described by Xie.90 In brief, 1 
mL of BSA solution (50 mg/mL in water) was prepared and 1 mL of HAuCl4 (1 x 10
-2 M) 
was added under stirring. After two minutes, 100 µL of NaOH (1 M) was added, and the 
solution was incubated at 37 ᵒC for 12 h. The BSA nanoclusters were washed three times 
with a Nanosep centrifugal device (Pall Corporation) and resuspended in 1 mL of PBS 
buffer (pH 7.4). 
II.3.i.f Protein Conjugation 
The heterobifunctional linker silane-PEG-NHS was used to conjugate cTnI and 
BSA on the nanoparticles.  Cardiac troponin I was conjugated on the nanoparticles to give 
them functionality (similar to the one described by Chon91) and to examine its activity 
after conjugation; however, it can be replaced by any other protein or antibody. To 
conjugate the proteins silane-PEG-NHS (440 µL, 4 x 10-4 M in ethanol/water 95%/5%) 
was added to 1 mL of the silica encapsulated nanoparticles obtained after the differential 
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centrifugation step. After reacting for 1 h, the nanoparticles were washed 3 times using a 
three step process of centrifugation (2000 g, 15 min), redispersion in sodium phosphate 
(400 µL), and sonication. This solution was added to a mixture of BSA nanoclusters (23 
µL) and 10 µg of cTnI. An additional 40 µL of BSA nanoclusters solution was added after 
15 min, and the reaction was incubated for 2 h at room temperature. TRIS buffer (550 µL, 
2 x 10-2 M, pH 7.5) and Tween 20 (5 µL, 8.9 x 10-2 M) were added afterwards to quench 
any reactive groups left. Lastly, the nanoprobes were washed 2 times using centrifugation 
(900 g, 10 min), redispersion in 1 mL of TRIS and 5 µL of Tween 20, and gentle mixing. 
II.3.ii Characterization  
TEM images of the nanoprobe were collected to analyze and verify the aggregation 
of silver nanoparticles, silica encapsulation, and the attachment of BSA-nanoclusters. 
BSA-nanoclusters were used as stabilizers to block spaces after conjugating the antigen 
and avoid nonspecific binding. In addition, the nanoclusters on the BSA were used as 
markers to identify the BSA conjugated around the nanoprobes on the TEM images. 
Figure 20 shows the comparison of the nanoprobes before (A and B) and after attaching 
cTnI and the BSA-nanoclusters (C and D). As can be noted, nanoclusters surround the 
silica nanoparticles indicating the attachment of BSA. 
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Figure 20. (A), (B): TEM images of aggregated Ag nanoparticles encapsulated in silica. 
(C), (D): TEM images of the silica encapsulated nanoparticles functionalized with cTnI 
and BSA nanoclusters (observed around the silica shell). 
 
The images also indicate that the nanoprobes are composed of different number of 
aggregated silver nanoparticles encapsulated in a silica shell with a thickness of 
approximately 20 nm. The nanoparticles were purposely aggregated to create hot spots 
between them and make a nanoprobe with a high enhancement factor. Aggregating the 
nanoparticles with NaCl resulted in variations in the amount of aggregation with 
nanoprobes containing different numbers of nanoparticles. A glycerol-based differential 
centrifugation method was used to separate the silica encapsulated nanoparticles with 
similar weight and reduce the level of polydispersity. However, after differential 
centrifugation, the collected silica encapsulated nanoparticles still exhibited some degree 
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of polydispersity with different numbers of aggregated nanoparticles. The resulting degree 
of polydispersity was not expected to cause inconsistent SERS signal per nanoprobe since 
it has been reported that in a nanoparticle cluster only one hotspot usually dominates the 
enhancement and the extra hotspots do not contribute significantly to the SERS signal.92 
The size of the nanoprobe was monitored at different steps of the functionalization process 
with the NTA as shown in Figure 21. The silver nanoparticles had a mean diameter of 57 
nm. These nanoparticles were aggregated and encapsulated in silica. The mean size of 
these silica nanoparticles was 92 nm. A 5 kDa PEG linker was attached to the silica to link 
the proteins to the nanoprobe, which increased the nanoprobe overall mean size by 19.5 
nm, or rather, the shell thickness by 9.75 nm. The length of a 5 kDa PEG chain on 
nanoparticles in a brush conformation has been reported to be 9.8 nm93, which agrees with 
the results obtained. Finally, conjugating the proteins increased the mean size of the 
nanoprobe by 13.74 nm to have a final size of 124.8 nm. The increase in thickness of 6.87 
nm after adding the proteins is also very similar to the hydrodynamic diameter of 7.4 nm 
that has been reported for BSA.94 The standard deviations on each step indicated the level 
of polydispersity in the nanoprobe size. However, the mean size increases at each step 
validate the successful functionalization of the nanoprobes.  
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Figure 21. Average diameter and standard deviation at different stages of the nanoprobe 
synthesis process. 
 
The extinction spectrum was also measured at each step to determine the localized 
surface plasmon resonance (LSPR). The LSPR is related to the aggregation state and the 
interparticle gap size between nanoparticles.92 Therefore, the appearance of peaks in the 
LSPR spectrum can be used as an indication that the nanoparticles are in close proximity 
or aggregated. Figure 22 shows the different UV/VIS spectra. The silver nanoparticles 
used had a single extinction peak at 416 nm. However, after the nanoparticles were 
aggregated a second peak around 575 nm was formed. The overall extinction values 
decreased after adding PEG and conjugating the proteins because the concentration of the 
nanoprobes solution decreased as particles were lost in the washing steps. Nevertheless, 
the two peaks were still observed after completion of all steps in the functionalization 
process indicating the stability of the silica encapsulated aggregates. 
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Figure 22. Extinction spectrum at different stages of the nanoprobe synthesis process. 
The second peak (at approximately 575 nm) indicates controlled aggregation. 
 
The zeta potential of the nanoprobe was measured to determine its surface charge 
at different stages of the functionalization process. This information was used to examine 
the nanoprobe electrostatic stability and to confirm that the surface was modified. As can 
be observed in Figure 23, the charge of the silver nanoparticles increases from -41 mV to 
-31 mV when they are encapsulated in silica. After attaching the PEG linker, the charge 
further increases to -20 mV, which can be attributed to the charge of the linker reactive 
group on ethanol before it reacts with a protein. After the proteins react with the functional 
groups, the charge decreases to its final value. The stability of a nanoparticle usually 
depends on a combination of electrostatic and steric effects, and it can be referred to as 
electrosteric stability.95 The use of a 5 kDa PEG linker and the attachment of cTnI and 
BSA served as steric stabilizers. The final zeta potential of the nanoprobe in a TRIS buffer 
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solution (pH 7.5) was -34 mV. This surface charge suggests the nanoprobe was 
electrosterically stable. 
 
Figure 23. Zeta potential at different stages of the nanoprobe synthesis process. 
 
A cardiac Troponin I ELISA kit was used to confirm that the conjugated cTnI can 
react with its antibodies after it is attached to the nanoprobe. The test also allowed 
approximation of the amount of cTnI proteins conjugated on a nanoprobe. Figure 24 shows 
the kit standard curve and the measured cTnI concentration when 100 µL of 2.81 pM and 
5.63 pM of nanoprobe was tested. The kit measurements and approximate calculations, 
using 26 kDa as the cTnI molecular weight, indicate there were an average of 112 cTnI 
proteins per nanoprobe (see SI for calculations). It should be noted that the nanoprobe 
absorbs at the wavelength used on the ELISA kit measurements; however, its contribution 
to the measured absorbance was minimal since a very low volume and concentration of 
nanoprobe was used. 
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Figure 24. ELISA kit results used to determine the amount of cTnI functionalized on 
specific concentrations of nanoprobe. Based on standard samples measurements a 
concentration curve with a fitted line was obtained to predict measured concentrations. 
 
 The SERS spectrum of the nanoprobe was measured to analyze its signal. Figure 
25 shows the peaks of the nanoprobe, which correspond the SERS spectrum of the RRM 
DTNB. As can be noted, the spectrum has several major peaks that can be monitored, 
specifically 1336, 1558, 1064, 1153, and 849 cm-1. Most of these vibrational peaks 
correspond to the nitro group stretching, or the aromatic ring stretching modes (see Table 
3). The narrow peaks of the spectrum allow to simultaneously measure different RRM 
spectra with peaks at different wavenumbers, and thus perform multiplexing 
measurements.  
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Figure 25. SERS spectrum of nanoprobe. The SERS spectrum corresponds to the 
Raman reporter molecule DTNB, which forms a SAM on the Ag nanoparticles. 
 
Table 3. DTNB Assignment Peaks. 
 
Peak (cm-1) Assignment Reference 
1336 Symmetric NO2 stretching 
96-97 
1558 Aromatic ring stretching mode 96-97 
1064 Aromatic ring modes 96-97 
849 Nitro scissoring vibration 96 
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II.4 Different Functionalities 
  The synthesized nanoprobes can be functionalized with different proteins or 
antibodies to give them the desired functionality. The conjugation strategy is the same for 
most proteins if they contain the targeted functional groups. The most common functional 
group is amine since it is present in the N-terminus of each polypeptide chain and in the 
side chain of lysine. The linker functional group used to conjugate proteins to the 
nanoprobe is NHS. Therefore, almost any protein can be conjugated without changing the 
linker functionality.  
 One of the main advantages of SERS is its multiplexing capability. Several 
nanoprobes can be detected simultaneously with the same excitation laser if the 
appropriate RRM are used. For multiplexing to work, RRM with peaks at different 
locations need to be utilized. Three RRMs (DTNB, MBA, and TFMBA) were selected to 
create nanoprobes with a different SERS spectrum. Figure 26 shows the spectrum of each 
nanoprobe. As can be observed on the spectrum with the combined nanoprobes, the 
narrow peaks of each nanoprobe can be detected. These three nanoprobes can be 
conjugated with antibodies for cTnI, myoglobin and CK-MB to develop an assay that can 
detect the three biomarkers at the same time.  
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Figure 26. SERS spectrum of nanoprobes functionalized with different RRM. (A) SERS 
spectrum of nanoprobe with DTNB. (B) SERS spectrum of nanoprobe with MBA. (C) 
SERS spectrum of nanoprobe with TFMBA. (D) SERS spectrum of a solution with the 
three different nanoprobes combined.  
 
II.5 Nanostars 
Gold nanostars were created to be used as alternative SERS active nanoprobes in 
the developed assays. Nanostars have been reported to be good SERS substrates due to 
the hotspots formed at their sharp edges. They provide the greatest enhancement when 
they are excited with a 780 nm laser. The nanostars were functionalized with RRM, 
encapsulated in silica, and conjugated with antibodies. They were also characterized to 
monitor the functionalization process and determine their SERS signal.  
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II.5.i Protocol 
A 20 nm citrate reduced Au colloid was synthesized first to be used as seed for the 
nanostars synthesis. To make the 20 nm Au colloid, 500 mL of DI water was added to a 
clean round bottomed flask with 50 mg of sodium tetrachloroaurate. The solution was 
heated until boiling. Then, 0.075 g of sodium citrate in 7.5 mL of DI water was added to 
the solution. The solution was boiled for 15 min and allowed to cool afterwards. 
Continuous stirring was maintained throughout the process.  
 The protocol to synthesize gold nanostars was based on the method described by 
Yuan.98 Briefly, 100 µL of the prepared citrate Au (Avg. size: ~12 nm, A520: 2.81) was 
added to 10 mL of 0.25 mM auric chloride (HAuCl4) solution (1.70 mg in 20 mL DI water) 
and 100 µL of 3 mM silver nitrate (AgNO3) in a 20 mL glass vial at room temperature 
under moderate stirring. After 5 min, 50 µL of 100 mM ascorbic acid was added, and the 
solution was left stirring for 15 min. To make the nanoparticles SERS active, 1 mL of 
nanostars solution was mixed with RRM, incubated overnight, and redispersed in ethanol 
after washing. The nanostars were then encapsulated in silica by adding APTMS (10 µL, 
0.001% in ethanol) to the solution, incubating for 10 min, washing, and redispersing them 
in IPA (1 mL), water (360 µL), and ammonium hydroxide (25 µL, 28%). After that, TEOS 
(10 µL, 1% in IPA) was added two times in an hour, incubated overnight, washed, and 
redispersed in ethanol. To conjugate antibodies on the nanoparticles, silane-PEG-NHS 
was added (400 µL, 2 mg/mL). The nanoparticles were washed and redispersed in sodium 
phosphate (400 µL, pH 7.4) to add 20 µL of cTnI antibody (1 mg/mL) and incubate the 
solution for 2 hrs. BSA was also added (20 µL, 50 mg/mL) to prevent nonspecific binding. 
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The nanoparticles were finally washed two times and redispersed in TRIS (1 mL, pH 7.5) 
and Tween 20 (5 µL, 1%). In Figure 27, the nanostars functionalization strategy is 
presented.  
 
Figure 27. Nanostar functionalization strategy. DTNB is attached to synthesized 
nanostars. Then, a silane-PEG-NHS linker is used to conjugate antibodies to the silica 
surface. 
 
II.5.ii Characterization 
The extinction spectrum was measured at three stages of the functionalization 
process (before functionalization, after silica encapsulation, and after protein attachment). 
As can be observed in Figure 28, the normalized extinction spectrum of the nanostars is 
red shifted after encapsulation and protein conjugation. The changes in the extinction 
spectrum is an indication that encapsulation was successful. It is important to note that in 
the absorbance measurements, the functionalized nanostars samples were more 
concentrated than the nanostars sample. Therefore, in the normalized spectrum the second 
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peak is more prominent than the first peak. Since the concentration of the nanostars sample 
was low, the two peaks can be clearly observed in the spectrum. Even though the spectra 
appear different because of the concentrations used in the measurements, the red shift of 
the second peak can be distinguished clearly. 
 
Figure 28. Nanostar extinction spectrum at different stages of the functionalization 
process.  
 
 The size of the nanostars was also monitored with a DLS instrument as they were 
functionalized. Figure 29 shows the increment in size as a silica layer was added and 
antibodies were conjugated. The size of the synthesized nanostars was approximately 126 
nm, and after encapsulation it increased to 152 nm. Thus, the silica thickness was about 
12.8 nm. The size of the nanoparticles further increased to 180 nm after attaching the PEG 
linker and the antibodies. The increase in thickness of 14.1 nm can be attributed to 9 nm 
of the 5 kDa PEG linker93 plus approximately 5 nm of the conjugated antibodies, which 
implies that the functionalization was successful. 
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Figure 29. Nanostar average size at different stages of the functionalization process. 
 
 SEM images of the functionalized nanostars were also obtained. Figure 30 shows 
an image of several silica encapsulated nanostars. In the image, the branches of the 
nanostars can be distinctly noticed. The silica around the nanostar makes the edges and 
tips of the branches appear soft. The size of the nanostars (around 150 nm) also matches 
the size measured with the DLS.     
 
Figure 30. SEM image of nanostars encapsulated in silica. 
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 The SERS signal of the nanostars was measured with a Sierra Series spectroscopic 
reader from Snowy Range Instruments (780 laser) to analyze it. As can be observed in 
Figure 31, the functionalized nanostars exhibited the expected SERS spectrum of the RRM 
DTNB. The characteristic peaks of the SERS spectrum could be distinguished clearly, and 
the signal intensity was high (about 18000 counts). This means that the nanostars could 
be used as SERS active nanoprobes for the development of biosensors. 
 
Figure 31. Nanostar SERS signal obtained with a Sierra from Snowy Instruments.  
 
II.6 Magnetic Particles 
 Magnetic nanoparticles were synthesized and functionalized to use them as 
components of the assays tested. These magnetic nanoparticles were not functionalized to 
be SERS active. They were conjugated with antibodies and other compounds or proteins 
to make them stable and prevent non-specific binding. The functionalized magnetic 
nanoparticles were also characterized. 
 
 62 
 
II.6.i Protocol 
 Superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized based on 
the method described by Lee.99 Briefly, ferric chloride hexahydrate (500 mg, 1.85 mmol) 
and ferrous chloride tetrahydrate (184 mg, 0.925 mmol) was added to deoxygenated DI 
water (30 mL) that had been degassed by bubbling with nitrogen gas for 20  min. Then, 
7.5 mL of ammonium hydroxide solution (28% in water) was added under nitrogen gas 
while stirring vigorously for 30 min. The remaining salt was removed by applying an 
external magnetic field to attract the particles and discard the supernatant. DI water (30 
mL) was added to the black precipitate, and the mixture was stirred gently to redisperse 
the particles. The particles were washed three times with water.  
 The SPIONs were encapsulated in silica for further functionalization. To do this, 
APTMS (10 µL, 0.001% in ethanol) was added to 1 mL of SPIONs, and the solution was 
incubated for 10 min. After that, the supernatant was removed by separating the 
nanoparticles with a magnet, and they were redispersed in IPA (1 mL), water (360 µL), 
and ammonium hydroxide (25 µL, 28%). Subsequently, TEOS (10 µL, 1% in IPA) was 
added two times in one hr. The solution was incubated overnight in a rotator, washed, and 
redispersed in ethanol. Silane-PEG-NHS (400 µL, 2 mg/mL) was added to the solution to 
be used as a linker to attach the antibodies. After incubating the solution for one hr and 
washing the nanoparticles three times, 20 µL of cTnI antibody (1 mg/mL) was added. BSA 
(20 µL, 50 mg/mL) was also added after 15 min to block unreacted groups. The 
nanoparticles solution was incubated 2 hrs and washed two times with TRIS base (1 mL, 
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pH 7.5) and 5 µL Tween 20 (1%). Figure 32 shows the schematic of the functionalized 
magnetic nanoparticles.    
 
Figure 32. SPIONs functionalization strategy. The SPIONs are encapsulated in silica, 
and a silane-PEG-NHS linker is used to attach the antibody to the silica surface.  
 
II.6.ii Characterization  
The size of the functionalized SPIONs was measured with a DLS (Malvern) 
instrument. The nanoparticles were approximately 168.7 nm after they were encapsulated 
in silica and the antibodies were conjugated. The extinction spectrum of the SPIONs was 
also measured. The extinction values were decreasing with increasing wavelength, and the 
spectra of the SPIONs before and after functionalization were very similar. To test if the 
magnetic nanoparticles could be magnetically collected, they were flowed on a 
microchannel with a magnetic area. However, most nanoparticles flowed past the 
 64 
 
magnetic area when they were injected at 1 µL/min. This suggested that the response of 
the SPIONs to the applied magnetic field was not strong enough. 
 The size of a magnetic particle can have an effect in its response to an applied 
magnetic field.100 Usually, larger particles are more strongly attracted to a magnetic field 
than smaller particles. Therefore, 1 µm magnetic particles were used to functionalize them 
and use them instead of the SPIONs. Dynabeads MyOne coated with streptavidin were 
obtained from Thermo Fisher Scientific. Since these magnetic particles were coated with 
streptavidin, biotinylated antibodies were used to conjugate them via the streptavidin-
biotin bond. After attaching the antibody, BSA was added to block free spaces and avoid 
nonspecific interactions. Figure 33 shows the 1 µm functionalized magnetic particle.  
 
Figure 33. Dynabeads MyOne coated with streptavidin to attach biotinylated antibodies. 
The diameter of the magnetic particle is 1 µm. 
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II.7 Chapter Summary and Conclusions 
In this chapter, several nanoparticle functionalization approaches were examined. 
The goal was to develop SERS active nanoparticles that (1) exhibit intense SERS signal, 
(2) are stable, and (3) are conjugated with a protein or antibody that makes them 
functional. The stability of the different approaches (summarized in Table 4) was used as 
the first criteria to select the best approach. The extinction spectra was measured in each 
case to test for aggregation, which usually indicates if the nanoparticles are stable. The 
first two functionalization approaches (Au-RRM-Antigen and Au-RRM-CAPEG-
Antigen) were not stable as they exhibited aggregation. In the third approach (Au-RRM-
PEG-Antigen), the nanoparticles did not aggregate, but they were sticking to the wall of 
the microtube. In the fourth approach (Au-RRM-Silica-PEG-Antigen), the Au 
nanoparticles were aggregated in a controlled manner; therefore, they exhibited stability.  
 
Table 4. Summary of functionalization approaches and their aggregation state. 
 
Approach Aggregation (Extinction) 
1: Au-RRM-Antigen Aggregated 
2: Au-RRM-CAPEG-Antigen Aggregated 
3: Au-RRM-PEG-Antigen Non-aggregated/Wall binding 
4: Au-RRM-Silica-PEG-Antigen Non-aggregated (controlled) 
5: Au-RRM-Silica-PEG-Antigen 
(modified 4 with Ag) 
Non-aggregated (controlled) 
6: Au-RRM-Silica-PEG-Antigen 
(modified 5 with linker) 
Non-aggregated (controlled) 
 
The SERS intensity of the nanoparticles was also considered in the selection 
process. From the first four approaches, the fourth approach (Au-RRM-Silica-PEG-
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Antigen) produced the most intense SERS signal. The fifth functionalization approach 
(Ag-RRM-Silica-PEG-Antigen) was very similar to the fourth; the only difference was 
that Ag nanoparticles were used instead of Au nanoparticles. In addition, a 532 nm laser 
was used as an alternative to the 780 nm laser to measure the SERS signal, which produces 
a more intense signal when silver nanoparticles are measured. In the sixth approach (Ag-
RRM-Silica-PEG-Antigen), a different linker (Silane-PEG-NHS) than the fifth approach 
was employed. This linker allowed better control over the functionalization process. The 
sixth functionalization approach was selected to develop the nanoprobe and use it as an 
assay component. After making the nanoprobe, it was characterized to monitor the 
functionalization process and test its functionality. 
As an alternative approach, SERS active nanostars were synthesized and 
considered as potential assay components. They were encapsulated in silica, 
functionalized with cTnI, and characterized. However, they were not selected because the 
nanoprobes produced a more intense SERS signal with the 532 nm laser. Magnetic 
nanoparticles or SPIONs were also synthesized and functionalized with antibodies to use 
them as capture nanoparticles in the assay. 
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CHAPTER III  
NANOPARTICLE COLLECTION METHODS FOR SERS MEASUREMENTS 
III.1 Need for Nanoparticle Collection 
One of the main challenges of SERS measurements is controlling their signal 
repeatability and performance since these can be affected by variations in substrate 
preparation or hot spots formation, which can be difficult to control.81, 92 The consistent 
collection of aggregated substrates in a specific area for SERS measurement can also have 
a significant effect on the repeatability. Therefore, an effort has been made to develop 
methods and techniques to produce consistent substrates and allow fine control over 
aggregation and collection for measurement.101 In general, SERS substrates are aggregated 
chemically, magnetically, or mechanically. Chemical methods of aggregation include 
adding solutions to change the electrostatic stability of the nanoparticles and induce 
aggregation.102 In addition, nanoparticles can be aggregated by functionalizing them with 
compounds, biomolecules, DNA strands, or other components that link them together.103 
Some groups have used magnets to aggregate or collect magnetic nanoparticles in specific 
areas to measure their SERS signal.104 SERS substrates have also been aggregated and 
collected in microchannels105, agglomerated silica particles106, and filter membranes107. 
However, the challenge of obtaining precise and sensitive measurements still exists, and 
improvements in nanoprobe synthesis and collection methods will greatly enhance the 
quality of SERS measurements. Typical requirements for high performance assays usually 
demand detection limits at the femtomolar (fM) level or below with a precision of less 
than 15 % CV.108-109 
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III.2 Centrifugation Wells Collection 
 One of the first methods used to collect the functionalized nanoparticles for SERS 
measurements was based on centrifugation. A device that allowed to place the sample on 
a well, centrifuge it, and measure the SERS signal on the well was designed and built. A 
sample with SERS active nanoparticles could simply be added to a microcentrifuge tube 
and centrifuged to collect the nanoparticles on the bottom. However, to measure the SERS 
signal on a confocal microscope, the bottom part of the centrifuge tube would need to be 
cut to be able to focus on the nanoparticles. This could affect the sample and thus the 
SERS measurement. In contrast, the developed collection method contained a well inside 
the microcentrifuge tube that could be removed to perform the SERS measurements. 
Figure 34 shows the device built.  
 
Figure 34. Device built to collect nanoparticles with centrifugation. The sample is 
placed inside the blue tube. Then, the microcentrifuge tube is centrifuged. After 
centrifugation, the blue tube is removed to measure the SERS signal on the small well. 
 
 The device was composed of a microcentrifuge tube, the cut bottom part of another 
microcentrifuge tube (which created the well), and a cut 1 mL pipette tip. It was assembled 
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by inserting the pipette tip to the well (as seen in Figure x). These two parts fitted tightly 
when they were joined. Then, this assembly was inserted in a regular microcentrifuge tube. 
The sample was added inside the pipette tip assembly. The microcentrifuge tube was then 
centrifuged (2800 rcf). The centrifugation force pulled the nanoparticles to the bottom of 
the well. After centrifugation, the pipette tip assembly with the sample was removed. The 
supernatant was discarded and the pipette tip was separated from the well (which 
contained the nanoparticles). The well was then placed under the confocal microscope to 
measure the SERS signal from the collected nanoparticles.  
 Different concentrations of SERS active nanoparticles were collected and tested 
on the centrifugation wells. Figure 35 demonstrates the images of several concentrations 
of nanoparticles collected on the wells. As can be observed, the nanoparticles were spread 
throughout the area and aggregated differently. A point where the nanoparticles were 
aggregated in each well was selected to measure the SERS signal. Figure 36 shows the 
SERS intensities obtained at specific concentrations. A volume of 200 µL of the 
nanoparticles solution was used for the measurements. Three different measurements of 
the same concentration were tested to calculate the standard deviation. The standard 
deviations obtained indicate that the collection of nanoparticles on the centrifugation wells 
is inconsistent. The intensities of the four lower concentrations tested show an increasing 
SERS signal trend as the concentration increases. Nevertheless, after a specific 
concentration the signal fluctuates and does not exhibit a pattern. 
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Figure 35. Images of nanoparticles collected on the bottom of the wells with the 
centrifugation microtube. 
 
 
Figure 36. SERS signal concentration curve of functionalized nanoparticles collected 
and measured on the wells of the centrifugation microtube device.  
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 This collection method offers a simple approach to collect nanoparticles using 
centrifugation and measure their SERS signal. However, the collection is not consistent 
and the nanoparticles aggregate differently, which affects the measurements repeatability.   
III.3 Magnetic Collection 
 A method based on magnetic force was also explored for the collection of 
nanoparticles. To use this method, magnetic nanoparticles were synthesized and 
functionalized. In addition, a magnet or an area with magnetic field was incorporated 
inside a microchannel or close to it. The magnetic nanoparticles would then be inserted in 
the microchannel, and they would be attracted and collected on the area with the magnetic 
field as they flow through. Several magnetic nanoparticles and magnetic field areas were 
tested to optimize the collection method.  
III.3.i Magnetic Pads 
One of the magnetic collection areas tested was the magnetic pads inside the 
microchannel. Nickel (Ni) 50 µm by 50 µm square pads (200 nm thick) were deposited 
onto a glass slide, and a PDMS microchannel was bound to the glass slide with the pads 
to contain them. To analyze if the magnetic pads could collect nanoparticles a magnetic 
nanoparticles solution was added to the microchannel as the collection areas were 
monitored under a microscope.    
The pads fabrication process is described in detail by Marks.110 Briefly, glass slides 
were spin-coated with lift-off resist (LOR). After exposure and development, the Ni 
pattern was visibly transferred onto the slides. Chromium (100 nm thick) and copper (50 
nm thick) were deposited on the pattern as the adhesion layer. Then, nickel (200 nm thick) 
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was deposited as the third and final magnetically responsive layer. After deposition, the 
photoresist layer was removed by placing the glass slide into a chemical stripper at 80 °C. 
The 100 µm thick microchannel was constructed via soft lithography. To do this, an 
uncured PDMS solution (10:1) was poured over a silicon wafer mold and cured at 65 °C 
for 2 hrs. After that, the PDMS microchannel was bound to the Ni pads patterned glass 
slide by plasma etching treatment. The nickel pads were magnetically activated by placing 
two attractive neodymium magnets on the sides of the microchannel and pads. Figure 37 
shows the magnetic pads. 
 
Figure 37. Microfluidic channel with nickel magnetic pads (B). Two permanent magnets 
need to be placed as shown in (A) to create the magnetic field on the pads. Each pad is 
50 µm x 50 µm and 200 nm thick.  
 
A solution of functionalized magnetic nanoparticles was injected to the 
microchannel with Ni pads at different flow rates. The induced magnetic field propagates 
down the magnetic pads, and the field is strongest at the centers and edges of the Ni 
magnetic pads.110 Therefore, the nanoparticles were expected to be collected on top of the 
pads as they passed through them. Figure 38 shows images of the pads as the solution of 
magnetic nanoparticles was flowing through them at different rates. The pads were 
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observed for 10 min as the fluid was pumped to the microchannels. In all the cases 
nanoparticles flowed through the pads without stopping, indicating that the magnetic force 
was not stronger than the flow to collect them. It is important to note that even though 
most nanoparticles passed through the pads, some of them were collected at the pads, 
especially when the flow was low. However, losing some nanoparticles could negatively 
affect the response of a sensor that depends on the effective collection of all the 
nanoparticles for quantification. Another concern with this design was the large area that 
would need to be probed to measure the SERS signal of the collected nanoparticles. Five 
50 µm by 50 µm pads would need to be mapped, which could take considerable time 
depending on the selected resolution. 
 
Figure 38. Images of the pads when magnetic particles (SPIONs) were flowing through 
them at different rates. (A) No nanoparticles can be detected on the pads. (B) Some 
nanoparticles can be detected on the top pad. (C) Some nanoparticles can be observed on 
the first four pads. 
 
In order to increase the magnetic force between the particles and the pads, larger 
magnetic particles (1 µm diameter) were used. These magnetic particles were considerably 
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more magnetic than the original ones. They could be collected in seconds if a magnet was 
placed next to a microtube containing a solution of them where it could take hours for a 
solution of magnetic nanoparticles in the same case. A solution of 1 µm magnetic particles 
was added to the pads at 1 µL/min to observe if all the particles were collected. Figure 39 
shows an image of the pads and the collected particles. As can be noted, most particles 
were aggregated between pads in the horizontal direction and some of them on top of the 
pads. The use of larger magnetic particles improve the collection considerably compared 
to the case when the smaller nanoparticles were used. Although more particles were 
collected, some of them passed through the pads and were lost, which is not desirable. In 
Figure 39 particles can also be observed on the microchannel above the pads area. In 
addition, the collection of the particles was not consistent as they were not localized on 
top of the pads. 
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Figure 39. Magnetic particles (Dynabeads, 1 µm) collected as a solution with them is 
injected through the pads. Some particles are aggregated between the pads or the sides of 
the microchannel. Other particles are not collected and pass through the magnetic pads.    
 
In addition to the square magnetic pads, another design was tested in which only 
one 200 µm diameter circular pad was used to collect magnetic particles (see Figure 40). 
The design intended to focus the particles in a small area. A small collection area would 
reduce the SERS measurements collection time or allow to probe more particles. However, 
in this case, the magnetic force of the circular pad was not strong enough to collect all the 
magnetic particles with a flow rate of 1 µL/min. Similarly to the previous design, some 
particles passed the circular pad when they were introduced. Figure 40 presents the 
collection of the particles on the circular pad. 
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Figure 40. Microfluidic channel with single circular nickel pad (200 µm diameter). (A) 
Dry microchannel. (B) Magnetic particles injected through the microchannel and 
collected on the circular pad.   
 
Nickel pads were patterned on a microchannel to create a magnetic field and collect 
magnetic particles on top of them. As magnetic nanoparticles and particles flowed through 
them at low flow rates some of them were collected, but others were not. The collection 
of large magnetic particles was considerably better than the smaller nanoparticles. 
However, the collection was not consistent and it had a high dependence in the flow rate.  
III.3.ii Magnet below Microchannel 
 The use of a magnet below a microchannel was another approach tested to create 
a magnetic area for collection of magnetic particles. In this case, a microchannel with an 
inlet and outlet was bonded on a glass slide, and a 3 mm diameter magnet was positioned 
below the glass slide and the microchannel. Magnetic particles were flowed through the 
microchannel to analyze their collection. 
 A silicon wafer mold with the microchannels design was created first to fabricate 
the microchannels. To produce the mold a silicon wafer was washed with acetone, then 
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IPA, and next with water. After drying it with air, it was placed on a hot plate for 1 min at 
65 °C, 2 min at 120 °C, and allowed to cool for 5 min. Then, it was paced on a spin coater, 
and 3 mL of SU8 photoresist was poured to the wafer. The spin coater was turned on with 
the appropriate settings. After that, the wafer was transferred to a hotplate to heat it for 6 
min at 65 °C and 15 min at 95 °C. The mask with the design was positioned over the wafer, 
and both were inserted on the UV exposure box. A long pass filter was placed on top of 
the mask before turning the UV box on.  After the UV exposure, the wafer was placed on 
the hotplate for 1 min at 65 °C and 5 min at 95 °C. The wafer was placed on a glass dish 
with SU8 developer, and it was swirled for 7 min. The wafer was then washed with IPA 
and dried with air. Finally, the wafer was heated for 1 min at 65 °C and 5 min at 120 °C.  
The microchannels were created by mixing PDMS polymer and curing agent in a 
10:1 ratio. Subsequently, the solution was poured on a petri dish on top of the silicon wafer 
mold. The petri dish was placed on a desiccator for 45 min to remove all the bubbles. 
Then, the dish was transferred to an oven to bake the PDMS for 20 min at 80 °C. The 
PDMS with the design was cut with a razor and separated from the mold. A glass slide 
and the PDMS design were placed on the plasma cleaner. After that, they were bonded to 
make the microchannels. Finally, the 3 mm diameter magnet was placed below the glass 
slide. Figure 41 demonstrates the microchannels with the magnet below. 
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Figure 41. Microchannels with permanent magnet (3 mm diameter) placed below. 
 
A solution with 1 µm magnetic particles was flowed through the microchannel to 
examine the collection area and asses if all the particles were collected. The solution was 
injected with a syringe and a microtube at a flow of 5 µL/min, and the magnetic area was 
monitored under a confocal microscope as the solution was flowing. In Figure 42 the 
magnetic nanoparticles can be observed as they are collected on the microchannel above 
the magnet. At the tested flow rate most particles were collected and very few flowed 
through the magnetic area. Some particles moved slowly on the magnetic area as the fluid 
was injected, but the flow force was not greater than the magnetic force, and thus the 
particles were not transported by the flow. The particles were transported by the flow only 
when the last volume of the injected solution passed thorough the magnetic area.  
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Figure 42. Images of magnetic particles collected on the microchannel. (A) Area above 
the permanent magnet where the magnetic particles are collected. (B) Zoom of the 
collection area. (C) Defined points in collection area to measure the SERS signal. 
 
 Although most magnetic particles were collected on the magnetic area, the area 
was too large to measure the SERS signal of most of the collected particles. Usually, a 
SERS reading takes 5 sec, and it has a spot size of 2.1 µm. Therefore, to probe several 
particles a map is defined with the number of points and distance between them that will 
be used to automatically measure the signals. Ideally, most particles would be measured 
in a short amount of time (approximately 10 min or less depending on the application). 
Nevertheless, if the particles are spread in a large area a significant amount of time would 
be needed to probe a considerable number of them, which is not desirable in many cases.  
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III.4 Membrane Collection 
A method to consistently collect nanoparticles on a specific area without losing 
any of them is desired to potentially improve the quality of SERS measurements. Besides 
chemical and magnetic approaches, mechanical methods can be employed to aggregate 
nanoparticles. Membranes with controlled pore sizes have been utilized in many 
applications to separate solutes in a solution based on their size. In this chapter, the use of 
a membrane to separate and collect nanoparticles was explored. Several designs were 
created and analyzed to determine their potential to collect nanoparticles for SERS 
measurements.  
III.4.i Plastic Wells 
 A device was built to contain a membrane and place the sample to be analyzed. 
This membrane collected SERS active nanoparticles when liquid containing the 
nanoparticles was aspirated through it. Multiple concentrations were passed through the 
membrane to analyze their collection and SERS signal. 
 The device was composed of two plastic squares and two rubber squares with a 
hole in the center and three smaller holes on the sides at identical positions to pass screws 
through them. The device was assembled in a specific order (as can be observed in Figure 
43). First, a rubber square was placed on top of a plastic square with their holes aligned. 
Then, an aluminum oxide 20 nm pore size membrane was positioned on the center to cover 
the middle hole. After that, the second rubber square was placed over the membrane with 
its holes aligned. The second plastic square was aligned and situated above the rubber 
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square. Finally, three screws were passed through the side holes to fasten the squares and 
sandwich the membrane.   
 
Figure 43. Device with membrane to collect nanoparticles. The 20 nm pore membrane is 
sandwiched between two rubber and plastic pieces with a hole in the center to collect the 
nanoparticles and three holes around it to insert screws and fasten the pieces.   
 
 The hole in the center of the assembly created a well with the membrane as the 
bottom. The solution with SERS active nanoparticles was added to this well (100 µL). 
Then, a tube connected to vacuum was placed below the hole and the membrane to aspirate 
the liquid through the membrane. As the liquid on the well was aspirated, the nanoparticles 
were trapped on the pores of the membrane. Since the sandwiched membrane was pressed 
between the rubber squares, the membrane was sealed around the holes. This prevented 
the liquid from leaking outside the well.  
 Several concentrations of SERS active nanoparticles were collected in the device. 
Then, the SERS signal was measured at selected points of the membrane. Figure 44 shows 
the SERS signal obtained at 1334 cm-1 for the concentration curve. The curve shows an 
expected response with increasing SERS values for increasing concentrations. The 
measurements were collected three times to calculate the coefficient of variations (CVs). 
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From 1.7 pM to 13.9 pM the CVs were greater than 10%, with values as high as 43% CV. 
In addition, the signals from concentrations below 3.5 pM could not be distinguished. 
These results suggest that the reproducibility and ability to measure low concentrations 
with this method would need to be further improved to be used in the development of a 
biosensor. The utilization of lower volumes and a smaller collection area could facilitate 
SERS mapping, which could contribute to signal improvement.  
 
Figure 44. SERS signal concentration curve of functionalized nanoparticles collected on 
the sandwiched membrane.  
 
III.4.ii Multiple PDMS Wells 
 Another filter-based collection device was designed and built to perform multiple 
measurements simultaneously. The device was based on the previous design in which a 
membrane was sandwiched between rubber and plastic structures with holes. It was tested 
by examining how nanoparticles were collected on the membrane. 
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 The device was constructed with PDMS slabs. Three PDMS slabs of different 
thickness were created by mixing PDMS polymer and curing agent in a 10:1 ratio. For the 
bottom slab, 22.5 mL of PDMS polymer was mixed with 2.5 mL of curing agent (25 mL 
total). For the middle layer, 9 mL of PDMS polymer was mixed with 1 mL of curing agent 
(10 mL total). For the top layer, 18 mL of PDMS polymer was mixed with 2 mL of curing 
agent (20 mL total). Each of the mixed solutions was added to a petri dish and left under 
vacuum for 40 min to remove air bubbles. After that, they were placed in an oven for 30 
min at 80 °C. Once the PDMS circle slabs were cured, the middle slab was aligned and 
positioned over the bottom slab to make multiple holes through them with a 1 mm hole 
punch at specific locations. Then, 5 mm holes were punched on the top slab at the same 
locations where the holes were made on other two slabs. This layer would form a well 
where the solution tested would be added. Before bonding the three layers, the filter 
membrane was placed between the holes of the bottom and middle layers. The membrane 
was cut into pieces large enough to cover the 1 mm hole. After all the holes had filter 
membranes of them, the layers were bonded by plasma treating them and joining them. 
Figure 45 shows the PDMS collection device. 
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Figure 45. PDMS collection device created by sandwiching pieces of a 20 nm pore 
membrane between two PDMS slices with holes in them to place the sample on top and 
suction it from the bottom.   
 
 The SERS active nanoparticles samples were introduced to the wells to collect the 
nanoparticles. The liquid on the wells was aspirated and passed through the filter 
membrane by connecting a tube to the bottom layer hole and applying vacuum. The 
nanoparticles collected on the membrane were examined with a confocal microscope to 
analyze how consistent they were collected. Figure 46 shows different wells explored. As 
can be noted, the collection was inconsistent. The nanoparticles were aggregated 
differently in the wells, which is not desirable because it affects reproducibility. 
Furthermore, sometimes the membrane was bent, and this caused the liquid to be aspirated 
under it as opposed of flowing through it. A rigid bottom layer with same size holes could 
solve this problem and make the collection method more reproducible.   
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Figure 46. Collection of nanoparticles in different wells of the PDMS collection device. 
The nanoparticles are inconsistently aggregated on the membrane. 
 
III.5 Membrane Collection Device 
Another device was built to collect nanoparticles with a filter membrane. However, 
this design addressed problems that previous designs exhibited. The collection device was 
composed of a rigid base with consistent holes. The holes were small enough to allow 
mapping in 15 min. Furthermore, the intersection between the hole and the membrane was 
sealed, which prevented leaks. Finally, this design allowed the testing of multiple samples 
without the need of a tube to apply suction. These improvements permitted the collection 
device to detect low limits of detection in a repeatable manner. 
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The device shown in Figure 47 was fabricated to consistently collect and aggregate 
functionalized nanoprobes and measure their SERS signal. The collection slide has holes 
and an aluminum oxide membrane with 20 nm pores. Since the membrane adheres to 
PDMS and PDMS to the acrylic slide without any adhesive, a PDMS layer was placed 
between the slide and the membrane to seal the membrane around the holes and avoid any 
liquid to be suctioned at any other point but the holes. The collection slide was built by 
drilling 457.2 µm holes on an acrylic slide, punching holes of similar size on the PDMS 
layer, and stacking the membrane on top of the PDMS layer. A CNC machine was used 
to drill the holes on the slide in a repeatable manner. The main priority was to consistently 
create sealed holes with the same diameter. 
 
Figure 47. Collection device. The device was built by placing a PDMS layer on top of 
an acrylic plastic slide, making holes through them (approximately 300 µm diameter), 
and placing a 20 nm pore membrane on top. The sample was placed on top of the 
membrane, and vacuum was applied at the bottom of the slide. 
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III.5.i Materials and Methods 
III.5.i.a Materials 
UVT acrylic microscope plastic slides were acquired from Ted Pella, Inc. (CA, 
USA). A polydimethylsiloxane (PDMS) Sylgard 184 kit was bought from Ellsworth 
Adhesives (WI, USA). Whatman inorganic membranes Anodisc 13 (0.02 µm pore size, 
13 mm diameter) were obtained from GE Healthcare Life Sciences (PA, USA).  
III.5.i.b Collection Device Fabrication 
A collection device was fabricated and built starting with the use of acrylic plastic 
slides (25 mm x 75 mm). A specified pattern of holes were drilled on two acrylic slides 
with a CNC machine. A thin layer of PDMS (2 mm) was created by mixing 20 mL of the 
silicone elastomer solution with 2 mL of the curing agent, adding the mixture to a big petri 
dish, leaving it in vacuum for 50 min, and heating it at 80 ᵒC for 45 min. A piece of the 
PDMS (25 mm x 75 mm) was cut and placed in the middle of the two plastic slides with 
their holes aligned. A dispensing needle (0.009 in inner diameter) was passed through the 
holes on the slides to pierce the sandwiched PDMS and create consistent holes on it. The 
top slide was carefully removed to avoid misaligning the PDMS slide and the bottom slide. 
Finally, 20 nm Anodisc filters were placed on top of the PDMS surface to cover the holes. 
III.5.i.c Collection Method and SERS Measurement 
The SERS signal of the nanoprobe was measured on the collection device. To do 
this, 10 µL of the sample was placed on top of the membrane above the hole, and vacuum 
(approximately -0.06 MPa) was applied with a tube below the slide to suction the liquid 
through the membrane and holes. After they were collected, the collection area was 
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focused on the Raman microscope and an 11 by 10 point grid with a step size of 40 µm 
and 45 µm respectively was defined to measure the SERS spectrum at each point. The 
intensity peak values at 1336 cm-1, which is a peak of the Raman reporter DTNB, of the 
measured spectra were used to plot maps and averaged to determine a value for the tested 
concentration. 
III.5.ii Testing the Membrane Collection Method 
III.5.ii.a Testing the Nanoprobes in the Collection Device 
Figure 48 shows the SEM images of the collection device with nanoprobes 
collected on the membrane. As can be observed, the nanoprobes are collected only on the 
areas in contact with the holes. When a low concentration of nanoprobes is passed through 
the membrane, they are spread throughout the area and the pores can be observed in the 
SEM image (Figure 48A-B). However, when a higher concentration of nanoprobes is 
analyzed, they cover all the area and form a thicker layer as they are stacked on top of 
each other (Figure 48E-F). The main function of the collection device is to gather together 
the nanoprobes in a small area and have the concentration of nanoprobes as the only 
changing variable in a SERS measurement. An effort was made to make the holes 
consistently and keep the aggregation area as similar as possible for each measurement. 
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Figure 48. SEM images of nanoprobes aggregated on the collection device. Low 
concentration: (A), (B) zoom. Medium concentration: (C), (D) zoom. High 
concentration: (E), (F) zoom. 
 
After gathering the nanoprobes with the collection device, the area was focused in 
the Raman microscope, and the SERS spectrum was measured at defined points on the 
collection area. SERS maps were plotted by using the intensity at 1336 cm-1 of all the 
spectra. Figure 49 shows the maps of the SERS intensity at 1336 cm-1 as different amounts 
of nanoprobe were analyzed on the collection device. As can be observed, the signal is 
mainly detected on the holes of the device. The signal increases with increasing 
concentration and reaches a maximum at 7.03 pM. At the blank measurement no signal is 
observed. 
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Figure 49. SERS intensity maps of different concentrations of nanoprobe collected on 
the collection device. To plot the maps, the SERS spectrum was measured at different 
points covering the collection spot (11 x 10 points, 40 µm and 45 µm step size 
respectively). Then, the peak values at 1336 cm-1 were used to obtain an intensity value 
for each grid point. 
 
The intensities at the specific wavenumber of interest of all the spectra measured 
in the grid to plot each map were averaged to obtain a single value for each collection spot. 
These values were then plotted with their corresponding concentration of nanoprobe used 
when 10 µL was tested. Three different measurements with the same amount of nanoprobe 
were tested to calculate the standard deviation. Figure 50 shows the curves obtained when 
different peaks of the nanoprobe spectrum were used to obtain a value for each 
measurement. The four peaks analyzed exhibited a similar trend as the concentration 
changed. In addition, as can be observed in the logarithmic plot, there is a portion that can 
be used to calculate a linear function to predict the concentration. At higher 
concentrations, the SERS signal flattens out and on average appears to decrease slightly 
but is effectively flat given the increase in standard deviation.  This standard deviation 
increase is likely due to the membrane saturating and more proteins, specifically BSA-
nanoclusters absorbing at the laser wavelength used for SERS excitation (532 nm), present 
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in the measurement area. It is expected that different concentration curves will be obtained 
if the dimensions of the hole are changed, which means that the collection device could 
be optimized for the desired response given a particular application. 
 
Figure 50. SERS values obtained for each concentration of nanoprobe tested when four 
different peaks of the DTNB spectrum were analyzed. Each point is the mean of the 
SERS intensity values at the specific wavenumber measured at different points on the 
nanoprobe collection area when 10 µL of the corresponding nanoprobe concentration 
was analyzed. 
 
III.5.ii.b Comparison of Nanoprobes with Ag-DTNB Nanoparticles 
The SERS signal concentration curve of the nanoprobe on the collection device 
was compared with the SERS signal concentration curve of Ag nanoparticles 
functionalized only with DTNB (Ag-DTNB). The same concentrations were used to test 
them in the collection device. As can be noted in Figure 51 the minimum concentration of 
nanoprobe that can be detected is about an order of magnitude lower than the concentration 
of Ag-DTNB nanoparticles. The LoD of the nanoprobe and Ag-DTNB nanoparticles of 
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the raw spectra measured on the collection device was calculated to be 16.2 fM and 517 
fM respectively. The collected spectra at each measurement point was also baseline 
subtracted using an algorithm based on a method described by Ning111 before averaging 
the intensities at 1336 cm-1 to obtain a value for each concentration. The LoD calculated 
with the baselined data improved to 12.9 fM for the nanoprobe and 190 fM for the Ag-
DTNB nanoparticles. The smaller LoD of the nanoprobe can be attributed to the consistent 
enhancement produced even after the nanoprobes are spread on the collection area at low 
concentrations. In each nanoprobe there are about 2 or more silver nanoparticles 
encapsulated in silica that interact with each other to form hotspots and enhance the signal 
of the DTNB molecule. In comparison, all the Ag-DTNB nanoparticles are aggregated on 
the membrane to form less controlled hotspots as they are not encapsulated. When the 
concentration is low, these nanoparticles spread on the collection area and less or no 
hotspots occur. 
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Figure 51. Comparison of signal obtained when the same concentrations of nanoprobe 
and Ag nanoparticles functionalized with DNTB were tested on the collection device. 
 
The coefficient of variation (CV) was also calculated for the replicate 
measurements of nanoprobe and Ag-DTNB nanoparticles gathered with the collection 
device to determine how precise this method can be. As can be observed in Figure 52, for 
nanoprobe concentrations between 0.1 pM and 3.5 pM their CVs were less than 10 % 
when raw data was analyzed. However, when baselined data was used for analysis, CVs 
were less than 10 % for concentrations between 27.4 fM and 1.76 pM. At higher and lower 
concentrations, their CVs were greater than 10 %, and this can be attributed to the 
previously discussed saturation for the higher concentrations and approaching the LoD for 
the lower concentrations. The CVs of the Ag-DTNB nanoparticles were more variable, 
with most CV values of less than 10 % obtained for concentrations higher than 0.43 pM 
(see Figure 52). 
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Figure 52. Coefficient of variations (CVs) of three replicate measurements at different 
concentrations of nanoprobe and Ag-DTNB measured with the collection method. (A) 
Nanoprobe CVs when raw or baselined spectra were used to calculate values. (B) Ag-
DTNB CVs when raw or baselined spectra were used to calculate values. 
 
III.6 Chapter Summary and Conclusions 
 In this chapter, several nanoparticle collection methods were designed, tested, and 
analyzed to determine an approach to consistently collect and measure SERS active 
nanoprobes. The first method tried consisted in using centrifugation to collect the 
nanoparticles. A device that facilitated the sample placement, centrifugation, and 
measurement was built; however, the collection was inconsistent. Magnetic collection was 
another method explored to gather magnetic particles at specific locations. A solution with 
magnetic nanoparticles was added into a microchannel with 50 µm by 50 µm magnetic 
square pads inside to test their collection ability. The magnetic nanoparticles were flowed 
at different flow velocities, and it was observed that most nanoparticles passed through 
the magnetic collection area. Magnetic particles of larger diameter (1 µm) were used to 
improve the collection, but many particles were still not collected. In an alternative 
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method, a 3 mm diameter magnet was placed below a microchannel to collect the magnetic 
particles. More particles were collected with this method, but the collection area was very 
large to measure the SERS signal.  
 A filter membrane with 20 nm pores was used to collect the nanoparticles in 
several subsequent approaches. A device was created with plastic and rubber squares that 
sandwiched the membrane and contained a hole in the middle to place the sample. The 
problem with this approach was the large collection area and the difficulty of assembling 
the device for every measurement. To improve this concept, PDMS slabs with holes were 
used to sandwich the membrane. This design allowed to test multiple samples 
simultaneously. Nevertheless, the flexibility of the bottom structure caused it to bend, 
which promoted leaks of the tested solution through the holes that resulted in inconsistent 
collection. A modified design was built with a solid base and consistent 300 µm holes that 
improved the collection efficiency. This collection device was tested by collecting 
different concentrations of nanoprobe. Nanoprobe samples (10 µL) were detected with 
less than 10 % coefficient of variation (CV) across a range from nearly 27.4 fM to 1.7 pM 
using the described collection method. 
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CHAPTER IV  
ASSAY DEVELOPMENT 
IV.1 Assay Formats 
 Assays are used to quantify the concentration of analytes in a sample. They are 
usually composed of antibodies or proteins that can selectively bind to the analyte of 
interest, even in the presence of multiple elements in a sample. An antibody can also form 
a strong bond with its analyte. These unique properties of antibodies are exploited to 
design assays. Several assay formats have been developed in which the procedures and 
the manner antibodies are used differ to obtain the desired results. The four main assay 
formats are: direct assay, indirect assay, sandwich assay, and competitive binding assay. 
Each assay format can be further customized by selecting the detection method, order of 
steps, and additional variables that affect the assay response.    
IV.1.i Direct Assay 
 The direct assay is a simple format with very few steps. In this format, the sample 
to be analyzed that contains the analyte of interest is incubated in a solid surface (plate or 
particle). The analyte then adsorbs to the surface to coat it. After this, a blocking solution 
is added to block available spaces in the solid surface. Subsequently, antibodies that bind 
to the analyte and are tagged with the detection compound (fluorescent dye, enzymes, etc.) 
are introduced to the solid surface. These antibodies bind to the analyte adsorbed on the 
solid surface. Then, the unbound antibodies are washed or removed from the capture area, 
and the signal produced by the labeled antibodies is measured. The signal is directly 
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proportional to the amount of antibody present. Figure 53 presents how the direct assay 
works. Advantages of this format include the minimal steps required to perform the assay.  
 
Figure 53. Direct assay format schematic. The analyte is adsorbed to the surface. Then, 
its labeled antibody binds to it and produces the signal.  
 
IV.1.ii Indirect Assay 
Another format very similar to the direct assay is the indirect assay. In this format, 
the analyte of interest is also incubated and adsorbed on a solid surface. After the analyte 
is adsorbed, the surface is blocked, and the antibody of the analyte is added. This antibody, 
or primary antibody, binds to the analyte on the solid surface. However, in contrast with 
the direct assay format, in this format the primary antibody is not labeled. Another species-
specific antibody, or secondary antibody, that is conjugated with a fluorophore or an 
enzyme is used to generate the measured signal. The secondary antibody, which binds to 
antibodies from the species of the primary antibody, binds to the primary antibody bound 
to the analyte. Figure 54 shows how the indirect assay works. An advantage to this format 
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is that several secondary antibodies can be bound to a primary antibody; therefore, the 
signal can be amplified and the sensitivity can be increased. Disadvantages of this format 
include an extra incubation step and the possible cross-reactivity of the secondary antibody 
that can cause background signal.  
 
Figure 54. Indirect assay format schematic. The analyte is adsorbed to the surface. Then, 
its antibody (primary) binds to it. After that, another labeled antibody (secondary) binds 
to the primary antibody to produce the signal.  
 
IV.1.iii Competitive Binding Assay 
 The competitive binding assay format is based on the competition between labeled 
analyte and the analyte in the sample of interest for antibody binding sites. This assay is 
usually used to measure small analytes. Since only one antibody is used in this format, 
competitive binding assays are also used when antibody pairs of an analyte do not exist. 
In this format, the antibody is usually attached on a solid surface. Then, a known amount 
of labeled analyte and the sample containing the analyte that will be measured are mixed 
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with the antibodies on the surface. Figure 55 shows the steps of a competitive binding 
assay. According to the law of mass action, the amount of free labeled analyte at a specific 
time will depend on the total amount of labeled analyte, total amount of sample analyte, 
total amount of antibody, and the association and dissociation rate constants of the analytes 
with the antibody. Therefore, when the concentration of sample analyte is high, less 
labeled analyte will be bound to the antibodies and more will be in the supernatant. In 
contrast, when the concentration of the sample analyte is low, more labeled analyte will 
be bound to the antibodies and less will be in the supernatant. The relationship between 
the signal and the analyte of interest concentration depends on which sample of the labeled 
analyte is measured. If the labeled analyte bound to the antibody is measured the signal 
will be inversely proportional to the analyte of interest concentration. However, if the 
labeled analyte in the supernatant is measured the signal will be directly proportional.  
 
Figure 55. Competitive binding format schematic. (A) The analyte competes with a 
labeled analyte for antibody binding sites. (B) The analyte binds to its labeled antibody. 
Then, any antibody with free binding sites binds to analyte conjugated on the surface.  
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In an alternative version of the competitive binding assay, the analyte is attached 
to a solid surface. Then, a known amount of labeled antibody and the sample interest are 
mixed and added to the surface. In this case, the analyte in the sample of interest will bind 
and occupy binding sites of the labeled antibody. If free antibody binding sites are 
available, the labeled antibody will bind to the analyte on the surface. As a result, the 
amount of labeled antibody free or on the surface will be depend on the amount of analyte 
in the sample. Additional modifications can be made to the competitive binding format, 
such as sequentially adding any of the components. Advantages of competitive binding 
assays include the flexibility of the detection methods, high sensitivity, the use of only one 
antibody, and the ability to perform the measurements in complex samples.    
IV.1.iv Sandwich Assay 
 The sandwich assay format is the most commonly used assay because it tends to 
be more sensitive and selective than other formats. In this format, two antibodies are used: 
the capture antibody and the detection antibody. Each antibody binds to a different site or 
epitope of the analyte. In a sandwich assay, the capture antibody is attached to a solid 
surface (well or particle). The surface is blocked to prevent non-specific binding. Then, 
the analyte is introduced to the area with the capture antibody. After some time, the analyte 
binds to the capture antibody, and the detection antibody is added. The detection antibody 
can be labeled with the detection compound (fluorescent dye, enzyme, etc.) or a labeled 
secondary antibody that binds to the detection antibody can be used. The detection 
antibody also binds to the analyte bound to the capture antibody. Consequently, the analyte 
is sandwiched between the two antibodies. Figure 56 shows the sandwich assay format. 
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As the concentration of analyte increases more labeled detection antibody is bound on the 
solid surface, and the signal obtained from the sandwich assay is proportional to the 
amount of analyte present. If a known amount of labeled detection antibody is added and 
the supernatant is measured, the signal is inversely proportional. Among the advantages 
of this assay format are its sensitivity, specificity, and flexibility of detection method. 
 
Figure 56. Sandwich assay format schematic. (A) The analyte is sandwiched between its 
capture and detection antibodies. The detection antibody is labeled to produce the signal. 
(B) The analyte is sandwiched between its capture and detection antibodies. Then, 
another labeled antibody binds to the detection antibody to produce the signal. 
 
IV.2 Selecting the Assay Format 
 An assay to detect cardiac biomarkers could have been developed in the different 
assay formats. To select the assay type to be used, the requirements of the biosensor and 
the characteristics of the assay formats were considered. The main requirements for the 
development of a cardiac biomarkers assay are high sensitivity, precision, and a fast 
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response. As discussed before, the assay formats differ in the steps, number of antibodies, 
and the way the analyte is detected. Each of them have advantages and disadvantages that 
affect the assay performance and its ability to meet the desired requirements. 
IV.2.i Direct and Indirect Assay 
In direct and indirect assays, the analyte of interest is adsorbed on a surface to 
detect it. Since the sample to be analyzed by the biosensor is composed of multiple 
proteins and other compounds, they will also be adsorbed on the surface. The surface then 
needs to be blocked to prevent the nanoprobes functionalized with detection antibodies to 
adsorb to the surface. The lack of control of which proteins or compounds and how many 
of them are adsorbed on the surface can increase the nonspecific binding of the nanoprobes 
and thus negatively impact the sensitivity and precision of the assay. In addition, the 
incubation time required for a blocking step after introducing the sample with the analyte 
would increase the assay detection time. For the indirect assay, having different proteins 
or antibodies on the surface could also increase the possibility of nonspecific binding 
caused by the interaction of the secondary antibody with them.  
 The adsorption of a protein on a surface is usually dominated by the surface energy, 
electrostatic interactions, and hydrophobic interactions.112 The bonds associated with 
adsorption are not as strong as covalent bonds, and can be disrupted by changing the pH, 
salt concentration or the addition of washing reagents. Since a washing step is required in 
both assay formats to separate the bound and unbound detection nanoprobes, the wash 
could also remove the adsorbed analyte of interest, which would cause inaccurate 
measurements. Furthermore, when the assays are translated to a microfluidic point-of-care 
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platform, the defined binding surface area would have to be composed of a different 
material than the channel walls to avoid adsorption in undesired sections. The failure 
potential associated with the direct and indirect assay formats prevented their selection as 
the formats for the development of an assay to detect cardiac biomarkers.     
IV.2.ii Competitive Binding Modeling 
 The competitive binding assay format can be designed in several versions to create 
a SERS based assay. The different versions of this format can be classified according to 
the order in which the reagents are mixed. For example, in the case in which an antibody 
is attached to the surface of a particle and the competitor is a SERS active nanoprobe 
functionalized with the analyte of interest on its surface, the following are the mixing 
possibilities: (1) simultaneous mixing - the nanoprobe and the sample with the analyte are 
mixed simultaneously with the antibody; (2) sequential saturation - the sample with the 
analyte is mixed with the antibody first, then the nanoprobe is added so it can bind in the 
available binding sites; (3) sequential displacement - the nanoprobe is mixed with the 
antibody first, then the sample with the analyte is added to displace the bound nanoprobe.  
 A model was created to predict and analyze the behavior of the sequential 
displacement competitive binding format. Specifically, the model calculated the free and 
bound amount of nanoprobe in the presence of different concentrations of analyte. The 
reagents concentrations and rate constants used were input in the equations of the model 
to obtain the predicted results.  
To create the model, the steps, components, and mechanisms of the sensor were 
defined. The sensor would consist in the filtration part, where the blood sample is filtered 
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to obtain the plasma with the analytes; the recognition part, where the analytes react in the 
assay; and the transduction part, where an element of the assay concentration is measured 
and converted to a quantitative value. Antibodies, functionalized nanoprobes, and the 
analyte of interest would be the three components of the assay. The assay would have a 
sequential displacement competitive binding format. In a competitive binding assay, the 
unknown concentration of an analyte of interest can be determined by measuring the 
concentration of the competing ligand, in this case the functionalized nanoprobes, that are 
free or bound to the receptor. 
In the envisioned sensor, recognition would occur in a microchannel. The 
antibodies or receptors would be attached to a surface inside the microchannel. In order to 
separate the flow in sections and control the assay reaction time, the microchannel would 
have three micro-valves that divide the channel in three sections: the assay or recognition 
section, the transduction section, and the waste section (see Figure 57). To prepare the 
sensor, the first step would be to add a small volume of functionalized nanoprobes solution 
to the microchannel. The transduction and waste micro-valves would be closed to allow 
the nanoprobes bind to the receptors in the assay section. After a period of time, the waste 
micro-valve would be opened to flush the liquid out of the assay section and leave the 
nanoprobe-antibody complexes ready for the next step. 
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Figure 57. Envisioned microchannel in which the sequential displacement assay occurs 
in the model. The channel has three sections: assay section where the reaction occurs, 
transduction section where the SERS signal is measured, and waste section. It also has 
valves to control the flow of reagents.   
 
To perform the test, a sample of blood would be obtained and filtered to separate 
the red blood cells from the plasma. The plasma would then be flowed to the assay section, 
where the competitive binding reaction would occur and the analyte of interest would 
displace the bound nanoprobes. The amount of nanoprobes that would be displaced would 
be proportional to the amount of analyte of interest present. After a specific time, the 
transduction micro-valve would be opened for a short time to separate the bound and free 
nanoprobes. Then, the micro-valve would be closed again and the free nanoprobes would 
be collected on the transduction section. Finally, the signal would be measured at the 
nanoprobes collection spot and processed to obtain the concentration of the analyte of 
interest. Table 5 shows the steps of the sensor and the equations used to model the system. 
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Table 5. Sequential displacement assay steps and equations used to model the system. 
 
 
  
Sensor Stage Equations in Model Time 
 
Initial State 
 
No equations  
 
Part I: Loading NPs 
 
 
 
60 
min 
 
Part II: NPs separation  
 
 
 
1 min 
 
Part III: Waiting for analyte of interest  
 
 
No equations 1 min 
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Table 5. Continued   
Sensor Stage Equations in Model Time 
 
Part IV: Competitive binding  
 
 
 
15 
min 
 
Part V: Competitive binding separation  
 
 
 
3 min 
 
Part VI: After competitive binding 
 
 
No equations 2 min 
 
 The equations that describe the model at the different stages of the sensor are 
derived from the law of mass action and the law of conservation of mass (shown in Table 
5). Since all the stages of the sensor are connected, the equations that describe the behavior 
of the sensor components in each stage are coupled with the equations that describe the 
behavior in previous and future stages. A final value (the amount of nanoprobes measured 
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after the sensor reaction with an amount of analyte of interest present) is obtained after all 
the equations are solved for each stage. Matlab was used to solve the ordinary differential 
equations of the system, couple the equations, and plot the responses to predict the 
concentration of NPs or the receptor-NPs complex at each point in time (see Figure 58).  
 
Figure 58. Model results that predict the amount of NPs in each section at each point in 
time for different concentrations of analyte tested. (A) Nanoparticles bound to antibodies 
in recognition section. (B) Free nanoparticles in recognition section. (C) Nanoparticles in 
waste section. (D) Nanoparticles in transduction section. (E) Zoom of nanoparticles in 
transduction section at the end of the assay. 
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As can be observed in Figure 58, the percentage of nanoprobes or antibody-
nanoprobes complexes at the defined areas (recognition area, transduction area, and waste 
area) is calculated for each point in time. The theoretical response of the sensor was 
calculated for four different concentrations of the analyte of interest: 0 M (blank), 8.38 x 
10-13 M (minimum), 8 x 10-8 M (medium), and 4.19 x 10-11 M (maximum). These values 
were selected because they are in the clinical cTnI concentration range of interest. The 
difference between the response when no analyte was present and when the maximum 
concentration of analyte was present can be observed in Figure 58E. As can be noted, the 
difference is approximately 0.008 % of the initial concentration of nanoprobes used (54.9 
nM) or 4.4 pM (difference between 11.130 nM and 11.126 nM). This value was obtained 
after optimizing the concentration values used of antibodies and nanoprobes to obtain the 
largest difference. The difference between the minimum and maximum concentrations is 
minimal compared to the actual concentration of nanoprobes that would be measured 
(about four orders of magnitude lower). This suggest that this assay version could be 
susceptible to errors that can affect the sensitivity or precision as any slight change could 
cause the same difference in signal. In other words, the signal to noise ratio (SNR) would 
probably be very small. Therefore, additional versions were considered to develop the 
biosensor.    
IV.2.iii Kinetic Rate Constants 
 The law of mass action is used to describe the behavior of reactants in a solution. 
Specifically, it states that the rate of a chemical reaction is directly proportional to the 
concentrations of the reactants.113 This interaction can be expressed as: 
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Equation 4 
RL 
ka
⇌
kd
 R +  L 
In this expression, R is the receptor, L is the ligand, RL is the receptor-ligand complex, ka 
is the association rate constant (M-1 s-1), and kd is the dissociation rate constant (s-1). The 
association rate constant kd is the amount of complexes formed per second in one molar 
solution of ligand and receptor and is used to describe the rate of complex formation. The 
dissociation rate constant kd is the fraction of complexes that dissociate per second and is 
used to describe the stability of the complex. The rate of change at time t of this reaction 
can be written as: 113 
Equation 5 
d[RL]
dt
= ka[R][L] − kd[RL] 
At equilibrium the ratio of the two rate constants gives the equilibrium association 
constant Ka, which represents the ratio of bound to unbound ligand and receptor. This is 
also known as the affinity constant and can be expressed as: 114 
Equation 6 
Ka =
ka
kd
=
[RL]
[R][L]
 
The inverse of the equilibrium association constant is the equilibrium dissociation constant 
Kd, which measures the tendency of a complex to reversibly dissociate into its components 
and can be written as: 114 
Equation 7 
Kd =
kd
ka
=
[R][L]
[RL]
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 The rates are related to the time the ligand is free or bound to the receptor. When 
a ligand gets sufficiently close to the binding site of a receptor it will bind and form a 
complex. The ligand will eventually dissociate when the random thermal movements of 
the complex produce enough energy to break the bond and allow the ligand escape.113 The 
average amount of time that a ligand will spend as part of a complex is the mean-life and 
is: 115 
Equation 8 
tmean =
1
kd
 
The time at which half of the initial amount of complexes have dissociated is the half-life 
and can be calculated by: 115 
Equation 9 
t1/2 =
0.693
kd
 
The mean-life and half-life are useful parameters that should be considered when 
designing assays. Table 6 present the half-life of different dissociation rate constants. As 
can be observed, complexes in a reaction can last from micro-seconds to days. This 
suggests that if receptors with a high kd are used in sandwich assay formats, they would 
dissociate in the washing steps and thus cause measurements errors. Similarly, if receptors 
with a very low kd are used in sequential displacement competitive binding formats a long 
time would be required to break the complexes.   
 
 
 
 112 
 
Table 6. Half-life of dissociation rate constants. 
 
kd (s-1) t1/2 
1 x 10-6 8 days 
1 x 10-5 19.2 h 
1 x 10-4 1.9 h 
5 x 10-4 23.1 min 
1 x 10-3 11.5 min 
5 x 10-3 2.3 min 
1 x 10-2 1.1 min 
1 x 10-1 6.9 sec 
1 x 101 69.3 msec 
1 x 105 6.9 μsec 
 
When a nanoprobe is functionalized with multiple analytes its dissociation 
constant will be different than the original analyte-receptor kd. This occurs because the 
probability of the nanoprobe to dissociate is reduced by the presence of additional analytes 
close to the receptor. The functional affinity or avidity of the nanoprobe is an accumulation 
of the affinities of individual interactions. The dissociation constant of cTnI with a specific 
antibody has been reported to be approximately 5.6 x 10-4 s-1.116 However, it is predicted 
that the dissociation constant of a nanoprobe functionalized with cTnI will have a lower 
kd and thus have a slower half-life. This means that it would take a long time for the 
complexes to dissociate and reach equilibrium in a saturation displacement competitive 
binding assay, which explains the small difference predicted in the model as different 
amounts of cTnI were tested. It takes approximately five times the half-time to reach 
equilibrium after the ligand and receptor are mixed.114 This would also negatively affect 
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the simultaneous mixing competitive binding assay as it would take a long time to reach 
equilibrium and measure the free nanoprobe proportional to the amount of cTnI present. 
In contrast, the sequential saturation competitive binding assay would not be affected by 
the half-time of cTnI and its antibody since the nanoprobes would only bind on the free 
binding sites, and after a couple minutes the free nanoprobes would be collected to 
measure them. Therefore, based on the model results, the dissociation rate constant, and 
half-time analysis of the complexes formed, it can be concluded that the sequential 
saturation version would probably be the best format to design a competitive binding assay 
to detect cTnI. 
IV.2.iv Selection between Sandwich and Sequential Saturation Competitive Binding 
Assays 
 After considering the different formats to design and develop an assay to detect 
cTnI, several of them were rejected and only two were identified as the most promising 
options. The assay can be designed in the sequential saturation competitive binding and 
sandwich assays formats. Both formats have different advantages and disadvantages that 
were considered to move forward in the assay development.  
 Both formats have the same number of steps: (1) mixing of analyte in the sample 
with the antibodies, (2) incubation of analyte and antibodies, (3) addition of functionalized 
nanoprobe, (4) incubation, (5) separation, (6) collection of nanoprobes, and (7) 
measurement. The main advantages of the competitive assay over the sandwich assay is 
that it only uses one antibody. The sandwich assay format requires antibody pairs that bind 
to different epitopes of the analyte. A main disadvantage of competitive binding assays is 
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that it is essential to control the concentrations of reagents used as any variations could 
affect the response.33 Although it would be ideal to control the reagents concentrations 
used for sandwich assays too, its response is not as sensitive to changes in concentrations 
used. Competitive binding assays can produce sensitive measurements; however, 
sandwich assays are considered the most sensitive and specific of all the assay formats 
when they are optimized and designed appropriately.33 As a result, the sandwich assay 
format was selected as the format to develop the cardiac biomarkers biosensor.        
IV.3 Sandwich cTnI SERS-Based Assay  
 A SERS-based sandwich assay was designed and developed to detect cardiac 
biomarkers. The main components of the assay included the functionalized nanoprobe 
synthesized to produce a specific SERS signal, a magnetic particle functionalized with the 
capture antibody, and a device to collect the nanoprobes for measurement. Figure 59 
shows the assay procedure steps. First, the sample with the analyte of interested is mixed 
with the magnetic particles, and they are incubated for approximately 20 min. Then, the 
nanoprobe is added, and the components are incubated for another 15 min. Subsequently, 
a magnet is used to separate the magnetic particles and extract the supernatant. After 
collecting the supernatant, buffer is added to the magnetic particles to wash them. The 
magnetic particles are separated again to collect the buffer. The collected supernatant is 
then passed through a membrane in the collection device to aggregate the nanoprobes on 
a specified area. Finally, specific points in the area are defined to measure the SERS signal. 
The monitored SERS peaks of the measurements are averaged to obtain an intensity value 
for the sample tested. 
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Figure 59. SERS-based sandwich assay procedure. The analyte is incubated with the 
magnetic particles. Then, the nanoprobe is added and incubated. After that, the particles 
are separated to collect the free nanoprobe and measure it.  
 
IV.3.i First Tests 
 To test the cTnI sandwich assay two concentrations were examined: one with cTnI 
(2000 ng/mL) and the other without (0 ng/mL). In this case, the magnetic particles were 
collected on the membrane to measure the SERS signal of the nanoprobes attached on 
them when cTnI was present.  
 The first step of the assay was to add 30 µL of cTnI in PBS or only 30 µL of PBS 
on a wellplate with 5 µL of magnetic particles. They were incubated for 30 min on a shaker 
at room temperature. Then, 10 µL of nanoprobe solution was added, and the solution was 
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incubated for another 30 min. After incubation, a magnet was placed on the bottom of the 
well to attract the magnetic particles and collect the supernatant. To wash the particles, 30 
µL of TRIS was added. This step was repeated one time. Finally, 10 µL of the magnetic 
particles solution was passed through the collection device to measure a SERS map.  
  Figure 60 shows the assay responses of the two different cases (blank and cTnI). 
The top images show the aggregated magnetic particles on the membrane with the defined 
points where the SERS signal was measured (blue marks). The bottom graphs are the 
corresponding SERS intensity maps (intensity value at 1333 cm-1 peak for each spectrum) 
obtained at the 110 different points. 
 
Figure 60. Sandwich assay results. Collected magnetic particles (A) and SERS intensity 
map (C) of blank sample. Collected magnetic particles (B) and SERS intensity map (D) 
of sample with cTnI (2000 ng/mL). 
 117 
 
 As can be observed, no significant difference was noticed between the two cases. 
Also, the SERS signal intensity of the few spots on the map was low (less than 1000 a.u.). 
SEM images of the tested magnetic particles were obtained to examine if nanoprobes were 
attached to them. In Figure 61, the nanoprobes (small white dots) can be observed on the 
magnetic particles in both cases. The nanoprobe attaching to the particles when no cTnI 
was present is an indication that nonspecific binding occurred. 
 
Figure 61. SEM images of the magnetic particles after the assay. (A) Magnetic particles 
of blank sample. (B) Magnetic particles of cTnI (2000 ng/mL) sample. The small white 
dots are nanoprobes. 
 
 Another similar test was performed; however, in this case more BSA was added to 
the particles after functionalization to block free spaces and avoid nonspecific binding. 
Also, three different amounts of magnetic particles were tested to determine if this variable 
had an effect in the assay response.  
In this assay, 30 µL of cTnI in PBS or 30 µL of only PBS was added to wells with 
different amounts of magnetic particles: 0.1 µL, 1 µL, and 2 µL. The solution was 
incubated for 20 min on a shaker at room temperature. Then, 2 µL of nanoprobe was added 
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and incubated for another 20 min. The particles were magnetically separated to wash them 
two times. Subsequently, they were redispersed in 30 µL of PBS and aggregated on the 
collection device to measure their SERS signal. 
The results of the assays at the two different cases can be seen in Figure 62. A 
slight increase of signal was noticed from the blank case to the cTnI case when 1 µL and 
2 µL of magnetic particles were used. However, the difference was very small. The 
opposite response was obtained when 0.1 µL was used, which was not expected. It is 
important to note that only small spots of SERS signal were observed in the maps, usually 
in the edge of the collection area. Furthermore, the addition of extra BSA to prevent 
nonspecific binding did not improve the signal, which suggested that other techniques 
would have to be examined.  
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Figure 62. SERS intensity maps of sandwich assays with different concentrations of 
magnetic particles. In (A), (C), and (E) a blank sample was tested. In (B), (D), and (F) a 
sample with cTnI was tested.   
 
IV.3.ii Use of Streptavidin/Neutravidin to Reduce Nonspecific Binding 
 Streptavidin and neutravidin were used in the antibody bioconjugation process as 
another method to prevent nonspecific binding and have more control over the amount of 
antibodies conjugated on the nanoprobe and magnetic particles. Magnetic particles coated 
with streptavidin were used to attach biotinylated antibodies. Similarly, the surface of the 
nanoprobe was coated with neutravidin to conjugate the biotinylated antibody sandwich 
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pair. Covering the surface of the nanoprobe and magnetic particles with 
streptavidin/neutravidin stabilized them without the need to cover them with antibody and 
BSA as previously done. In previous conjugation techniques, antibody and BSA had to be 
added in excess of the amount of NHS-active PEG present on the nanoprobes to avoid 
crosslinking since the proteins have more than one amine groups. Adding neurtravidin in 
excess prevented crosslinking, nonspecific binding, and permit the attachment of the 
desired amount of antibody. 
 The assay procedure was similar to the previous tests. Briefly, the samples to be 
tested (blank and cTnI or low cTnI and high cTnI) were added to wells with different 
amounts of magnetic particles (1 µL, 2 µL, or 5 µL). They were incubated for 20 min on 
a shaker at room temperature. Then, 2 µL of nanoprobe was added and incubated for 
another 20 min. After this, the particles were washed two times and resuspended in 30 µL 
of PBS. In two assays, the magnetic particles were aggregated on the collection device to 
measure their SERS signal. However, in one assay 5 µL of the supernatant solution was 
passed through the collection device to aggregate the nanoprobes that did not bind and 
measure their SERS signal. 
 Figure 63 shows the SERS intensity maps of the different cases: blank and cTnI 
(1666 ng/mL) for 2 µL and 5 µL of magnetic particles used and low cTnI (1 ng/mL) and 
high cTnI (10 ng/mL) for 1 µL of magnetic particles used. A slight decrease of signal was 
observed from the high cTnI to the low cTnI cases when 1 µL of magnetic particles was 
used, which was expected. However, the difference was minimal. A similar response was 
observed for the 2 µL of magnetic particles case when blank and cTnI were tested. It was 
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noted that the SERS map intensity was low at the center of the collection spot and high 
around the spot. In the case where the supernatant was measured and 5 µL of the magnetic 
particles were used, the results were also as anticipated because the blank sample resulted 
in higher signal than the sample with cTnI. This should happen because the amount of 
nanoprobe on the supernatant is inversely proportional to the amount of cTnI added. Even 
though all the results followed the expected trend, the difference in SERS signal was not 
very high (the largest intensity difference was 1061 a.u. between blank and cTnI when the 
supernatant was measured). This suggested that optimization of the assay would be needed 
to improve the response.      
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Figure 63. SERS intensity maps and collection images. Assay responses of two different 
cases: blank and cTnI samples when 2 and 5 µL of magnetic particles were used, and 
high (10 mg/mL) and low (1 ng/mL) cTnI samples when 1 µL was used. (A1), (A2), 
(B1), (B2) show the SERS intensity maps of the aggregated magnetic particles on the 
membrane. (C1) and (C2) show the SERS maps of the aggregated supernatant. 
 
IV.3.iii Antibody Selection Pair Test 
Monoclonal antibodies bind to a specific region or epitope of their antigen. For 
many antibody clones, the amino acids of the antigen they target have been identified. 
This information as well as empirical tests are used to determine the antibody pairs that 
target the antigen at different regions in order to be used in sandwich assays. In an effort 
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to find the sandwich pair that resulted in the largest difference between blank and cTnI 
different antibodies combinations were tested. 
  Three different antibody clones were used to test different combinations. Two 
antibodies were biotinylated, and other two were not. Table 7 shows the capture and 
detection antibodies combinations. After bioconjugating the antibodies on the magnetic 
particles (with streptavidin) or the nanoprobe (with neutravidin or with NHS linking), they 
were used to test a blank sample and a sample with cTnI (100 ng/mL). 
 
Table 7. Capture and detection antibodies combinations.  
 
Capture Antibody 
on Magnetic 
Particle 
Detection Antibody 
on Nanoprobe 
19C7-Biotin 560 
4C2-Biotin 19C7 
4C2-Biotin 560 
4C2-Biotin 19C7-Biotin 
 
In the assay, 30 µL of the sample was added to 15 µL of magnetic particles. They 
were incubated for 30 min on a shaker at room temperature. Then, 2 µL of nanoprobe was 
added and incubated for another 30 min. The supernatant was collected as the particles 
were washed two times and redispersed in 30 µL of PBS. Then, 5 µL of the supernatant 
solution was passed through the collection device to measure the SERS signal.  
The assays results are shown in Figure 64. As can be noted, the pair that 
demonstrated the largest difference between the blank and cTnI cases was the 4C2-biotin 
– 560. The 4C2-biotin – 19C7 pair also demonstrated a difference between the two tested 
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cases. In contrast, the 19C7-biotin – 560 sandwich pair resulted in the opposite expected 
result as the supernatant SERS signal of the blank case was lower than the signal of the 
cTnI case. The 4C2-biotin – 19C7-biotin pair resulted in almost no difference. These 
results implied that the 4C2-biotin – 560 pair should be used for further tests of the 
sandwich assay. 
 
Figure 64. SERS intensity maps of collected nanoprobes when 100 ng/mL cTnI (for A1, 
B1, C1, and D1) and blank samples (for A2, B2, C2, and D2) are tested using distinct 
sets of capture-detection antibodies. The difference between the mean values of the two 
samples tested for each set was calculated to determine the pair that resulted in the 
greatest difference. 
 
 The sandwich pair that resulted in the largest difference was used to test several 
cTnI concentrations. To do this, 30 µL of the samples (100, 50, 10, 5, 1, 0.5, 0.2, 0.02, and 
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0 ng/mL) were added to wells with 15 µL of magnetic particles. The samples was 
incubated for 20 min. Then, 1 µL of nanoprobe was added to incubate them for another 
20 min. After washing two times, 2.5 µL of the supernatant was passed through the 
collection device to measure the SERS signal. 
The concentration curve obtained for the tested sandwich pair was not as expected. 
As can be seen in Figure 65, no significant trend was detected. In the ideal case, the SERS 
values decrease with increasing concentration of troponin. Several factors, including 
nonspecific binding, the amount of the assay components used, the activity of the 
antibodies, or the condition of the cTnI protein sample tested, could have caused the 
response obtained.  
 
Figure 65. SERS-based sandwich assay concentration curve obtained when magnetic 
particles were conjugated with the 4C2-biotin antibody and nanoprobes with the 560 
antibody. 
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IV.3.iv Troubleshooting with ELISA Kit 
 A cTnI ELISA kit obtained from GenWay (CA, USA) was used to analyze some 
of the components of the developed assays. It was expected that by comparing the results 
from the kit with the results obtained by using components of the developed SERS-based 
assay problems could be identified. Specifically, prepared cTnI samples of several 
concentrations were tested on the kit and compared with the standard samples. In addition, 
the functionalized magnetic particles were used, instead of the kit wellplate, in conjunction 
with the enzyme labeled antibody solution from the kit to test samples. 
 The steps for the tests were based on the kit assay procedure. First, 100 µL of 
standards and the samples to be analyzed were added to the wells. Then, 100 µL of enzyme 
conjugate reagent was added, mixed, and incubated for 90 min at room temperature. After 
incubation, the mixture was removed, and the wells were washed 5 times with deionized 
water. Subsequently, 100 µL of TMB reagent was added into each well and incubated for 
20 min at room temperature. To stop the reaction, 100 µL of stop solution was added. 
Finally, the absorbance at 450 nm was measured. To test the magnetic particles the 
previous steps were performed on a well with 10 µL of magnetic particles. Two magnetic 
particles functionalized with the 19C7-biotin and 4C2-biotin antibody clones respectively 
were tested. The particles were washed by using a magnet to collect the particles on the 
well and remove the supernatant. Table 8 and Table 9 show the samples and concentrations 
tested for the different cases.   
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Table 8. Samples and results from the ELISA kit tests. 
. 
Sample 
Concentration 
(ng/mL) 
Volume 
Added (µL) 
Absorbance 
Standard 1 0 100 0.0544 
Standard 2 2 100 0.0578 
Standard 3 7.5 100 0.0604 
Standard 4 30 100 0.1050 
Standard 5 75 100 0.1671 
cTnI 0 100 0.0570 
cTnI 0.2 100 0.0560 
cTnI 1 100 0.0552 
cTnI 10 100 0.0651 
cTnI 100 100 0.1706 
 
 
Table 9. Samples and results from the ELISA kit tests using magnetic particles. 
 
Sample 
Concentration 
(ng/mL) 
Volume 
Added (µL) 
MNPs-19C7 
Absorbance 
MNPs-4C2 
Absorbance 
Standard 1 0 100 0.0664 0.0528 
Standard 3 7.5 100 0.1270 0.0550 
Standard 5 75 100 0.8366 0.0598 
cTnI 0 100 0.5424 0.5846 
cTnI 10 100 0.6964 0.5919 
cTnI 600 100 3.9038 1.4960 
 
 Figure 66 shows the results obtained when the standards and the prepared 
recombinant cTnI solutions were tested with the kit and the magnetic particles. As can be 
seen in Figure 66A, for the samples tested with the kit the absorbance increases with 
increasing cTnI concentrations. However, when the magnetic particles were used instead 
of the kit coated wells the results were different for the standard and the prepared cTnI 
samples. The absorbance values of the prepared recombinant cTnI samples were higher 
than the standards for similar concentrations (see Figure 66B, and Figure 66C). In 
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addition, the difference of antibody clonality had an effect in the response obtained. For 
the magnetic particle functionalized with 4C2 antibody minimal absorbance change was 
observed for increasing concentrations of the standard samples. Conversely, absorbance 
values increased with increasing concentrations of the standard sample for the magnetic 
particles functionalized with the 19C7 antibody clone, suggesting that cTnI binds 
specifically to the particles. The flat response obtained when the 4C2 antibody was used 
can be explained if the antibody from the kit (labeled with the enzyme) attaches to the 
same cTnI epitope as the 4C2 antibody conjugated on the magnetic particles.  
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Figure 66. ELISA kit results. (A) Concentration curve obtained when the standards and 
prepared cTnI samples were tested with the kit. (B) and (C) are the concentration curves 
obtained when magnetic particles (conjugated with (B) 19C7 antibody and (C) 4C2 
antibody) were used with the kit to test the standards and prepared cTnI samples.  
 
 An important result to note is the different values obtained for the two different 
blanks on the magnetic particles tests. In Figure 67 the measured blank values of the 
standard and the prepared cTnI sample (PBS buffer only) tested on the magnetic particles 
can be compared. The values of the PBS buffer are considerable higher than the blank 
standard, and this occurs without any cTnI present in the sample. This implies that 
antibodies attach to the magnetic particles without the presence of cTnI and after blocking 
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them with BSA. The fact that a low signal was obtained with the blank standard suggests 
that the solution contains something that prevents nonspecific binding. This also suggests 
that for future tests BSA or another compound needs to be added to the cTnI sample 
solution to prevent nonspecific binding. The results obtained in previous assay tests could 
have been affected by not adding anything to the tested samples that prevents nonspecific 
binding.  
 
Figure 67. Comparison between a standard blank sample and a prepared blank sample. 
The samples were tested with an ELISA kit using two antibodies (19C7 and 4C2).  
 
IV.3.v Addition of BSA to Dilution Buffer 
 The previous results demonstrated that the composition of the dilution buffer used 
to prepare cTnI samples has a significant impact in the assay response. Nonspecific 
binding can be reduced considerably if the dilution buffer contains stabilizing agents that 
prevent it. Therefore, different buffers were prepared, tested, and compared with the 
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standard blank sample of an ELISA kit to assess their ability to prevent nonspecific 
binding and be used as dilution buffers for the preparation of assay samples.  
 BSA and Tween 20 are commonly used in assays to reduce nonspecific binding. 
Also, the sodium chloride concentration can have an effect in the antibody binding 
reaction. As a result, PBS and TRIS buffers with several concentrations of BSA, Tween 
20, and sodium chloride were prepared. Table 10 shows the composition of the different 
buffers made. 
 
Table 10. Dilution buffers composition. 
 
Buffer BSA (%) Tween 20 (%) NaCl (M) 
PBS 0 0 0.15 
PBS 1 1 0.05 0.15 
PBS 2 2 0.10 0.30 
PBS 3 3 0.10 0.50 
TRIS 0 0 0 
TRIS 1 1 0.05 0.15 
TRIS 2 2 0.10 0.30 
TRIS 3 3 0.10 0.50 
 
 The ELISA kit employed previously was utilized to test the effect of the buffers 
on the signal. The assay protocol was the same as described before. Magnetic particles 
functionalized with two different cTnI antibodies (19C7, 4C2) were used for the tests 
instead of the kit wells. The samples tested were the prepared buffers plus the blank 
standard for comparison.  
Figure 68 shows the absorbance values obtained for each sample (identified with 
the percentage of BSA present). As can be noted, in all cases, except the PBS and TRIS 
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buffers without BSA or Tween 20, the signal was the same as the standard blank sample. 
This indicates that any of the buffers with different formulations of BSA and Tween 20 
could be used as dilution buffers, but buffers without BSA and Tween should not be used. 
The results were similar for magnetic particles functionalized with different antibodies. 
 
Figure 68. Dilution buffers effects on the measured signal. The blank samples were 
tested with an ELISA kit. Only when dilution buffer without BSA was utilized 
nonspecific binding occurred.  
 
 Since no BSA or Tween 20 was used to prepare cTnI samples in previous assay 
tests, the assay was tested again with cTnI samples prepared in dilution buffer containing 
1% BSA and 0.05 Tween 20 (PBS 1 buffer). The cTnI samples (30 µL of 0, 1, and 621 
ng/mL) were incubated with 5 µL of magnetic particles (conjugated with 4C2-biotin 
antibody) for 20 min at room temperature. Then, 2 µL of nanoprobe (conjugated with 
19C7-biotin antibody) was added and incubated for another 20 min. The particles were 
washed, and 2.5 µL of the supernatant was collected on the collection device to measure 
the SERS signal. 
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 The assay results, shown in Figure 69, indicate that the SERS signal is highest at 
the blank sample and lowest at the high cTnI concentration (621 ng/mL), which was the 
expected response. The addition of BSA and Tween 20 to the sample dilution buffer 
reduced nonspecific binding and allowed the assay to detect different concentrations. 
However, more studies need to be conducted to evaluate the assay performance.  
 
Figure 69. SERS intensity maps of collected nanoprobes when 0, 1, and 621 ng/mL of 
cTnI were tested. A dilution buffer with BSA was used to prepare the samples. 
 
IV.3.vi Sandwich SERS-Based Assay Concentration Curve Analysis 
 Several cTnI concentrations (0, 0.01, 0.1, 0.2, 0.5, 0.8, 1, 5, and 10 ng/mL) were 
measured with the SERS sandwich assay to plot a concentration curve. Each sample was 
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tested three times to calculate the standard deviation. The assay procedure was the same 
as previous tests. First, 30 µL of sample was mixed with 5 µL of magnetic particles and 
incubated for 20 min. Then, 2 µL of nanoprobe was added and incubated for another 20 
min. The particles were washed two times, and the 2.5 µL of the supernatant was collected 
on the collection device to measure the SERS signal. It is important to note that in this 
case, the background signals were not considered when the different measured points were 
averaged to obtain a value for each sample measured on its collection area.  
 It was expected that the SERS signal would decrease with increasing cTnI 
concentrations. As can be noted in Figure 70, this anticipated trend was observed. The 
SERS signals of the 1, 5, and 10 ng/mL samples were lower than the signals of the lower 
concentrations. The largest signal difference occurred between 0.5 and 1 ng/mL. Only one 
sample (0.8 ng/mL) was measured between these two samples, and its signal was 
approximately halfway between their signals, which was expected. However, the standard 
deviation of this measurement was very high. At concentrations above 1 ng/mL the signal 
did not decrease further, and at concentrations below 0.5 ng/mL the signal appeared to 
decrease slightly, but the values were still higher than the 1, 5, and 10 ng/mL samples. A 
four parameter logistic model was used fit a curve to the measured points. As can be 
observed in Figure 70, the fit was not ideal (it had an R-square of 0.87), but it indicated 
the trend.  
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Figure 70. SERS-based sandwich assay concentration curve obtained when magnetic 
particles were conjugated with the 4C2-biotin antibody and the nanoprobes with the 
19C7 antibody. A dilution buffer with BSA was used to prepare the cTnI samples. 
 
The results suggest that the dynamic range of the sensor occurs between 0.5 and 1 
ng/mL. The goal is to develop a cTnI assay that can measure cTnI from 0.01 ng/mL to 1 
ng/mL with less than 10% CV. This means that these two concentrations should be 
included in the ideal dynamic range. If 0.01 ng/mL and 1 ng/mL are included in the 
dynamic range, the concentrations between these values can be predicted with the 
measured signal. Ideally, the SERS signal of the blank concentration should also be 
different (in this assay higher) than the lowest concentration of interest (0.01 ng/mL). 
Since the current dynamic range is from 0.5 to 1 ng/mL, the assay needs to be able to 
detect lower concentrations or it needs to be more sensitive to span across the range of 
interest. The current limit of detection (LoD) can be estimated to be higher than 0.5 ng/mL 
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based on the standard deviations of the measurements and the observed dynamic range. 
Furthermore, the repeatability of the responses should improve to meet the precision 
requirements. Although a trend is observed with the current assay, it needs further 
optimization to achieve better sensitivity and precision across the range of interest. 
Variables such as the amount of components used, amount of antibody conjugated to the 
particles, blocking agents, and mixing conditions that improve the response need to be 
controlled and analyzed to find the optimal values. 
IV.4 Chapter Summary and Conclusions 
In this chapter, the different assay formats were explained. They were analyzed to 
determine the ones that could be used to implement the cTnI assay. The sandwich assay 
and the competitive binding assay were identified as the most promising formats for the 
desired application. Furthermore, it was recognized that the competitive binding assay 
could be implemented in three different versions: simultaneous mixing, sequential 
displacement, and sequential saturation. A model was created to predict the response of 
the sequential displacement version. The model predicted a minimal difference between 
the minimum and maximum analyte concentrations tested. An additional kinetic rate 
constants analysis suggested that the sequential saturation competitive binding assay and 
the sandwich assay were the most promising formats to develop the cTnI assay. The 
sandwich assay format was ultimately selected to implement the assay with the 
synthesized nanoprobe, the functionalized magnetic particles, and the collection device. 
Initial assay tests indicated the presence of nonspecific binding. To address this, 
the particles were blocked with an excess of BSA. Also, neutravidin and streptavidin were 
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conjugated on the nanoprobe and the magnetic particles respectively to attach biotinylated 
antibodies, control the amount of antibody conjugated, and reduce nonspecific binding. A 
response that was expected, but with minimal change, was observed after introducing the 
changes. Additional tests with several antibody pairs were conducted to identify the best 
pair. In troubleshooting experiments, it was found that adding BSA to the sample dilution 
buffer was essential to reduce nonspecific binding. A clear improvement in the assay 
response was observed after using dilution buffer with BSA in the tests. Finally, a 
concentration curve was measured using the optimized parameters. The expected trend 
was observed in the test. However, it was concluded that additional assay optimization is 
needed to detect lower concentrations (0.01 ng/mL) with better repeatability (less than 
10% CV).      
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CONCLUSIONS 
 The goal of this work was to develop a SERS-based assay to detect cardiac 
biomarkers. To do this, the assay components were created first. Different nanoparticles, 
such as Ag and Au, were synthesized and functionalized with RRM. These SERS active 
nanoparticles were then conjugated with antibodies and other proteins. Multiple PEG 
based linkers were used to attach the proteins to the surface of the nanoparticles. In some 
cases, the nanoparticles were aggregated and encapsulated in silica. This enhanced the 
SERS signal to create nanoprobes with high SERS intensity that could be used in assays 
to detect low levels of analyte. The stability of the nanoparticles was achieved by using 
hydrophilic linkers and stabilizing proteins such as BSA. After comparing the stability 
and SERS signal of the nanoparticles functionalized in different manners, if was found 
that the silica encapsulated Ag nanoparticles exhibited stability, the highest SERS signal, 
and successful bioconjugation of cTnI or cTnI antibodies. Therefore, this nanoprobe was 
selected to be used in assay experiments moving forward. Magnetic nanoparticles were 
also synthesized and functionalized with antibodies to be used as the analyte capture 
components in the assay. 
 To collect the SERS active nanoparticles for measurement several techniques were 
explored. A microchannel with magnetic pads was tested to determine if nanoparticles 
could be captured on them at different flow velocities. The synthesized magnetic 
nanoparticles used for these tests were not able to be collected. Therefore, magnetic 
particles of larger size (1 µm) were used instead. The use of larger particles improved the 
collection on the magnetic areas; however, not all the particles were collected, and the 
 139 
 
collection was not localized in a small area, which is ideal for SERS measurements. As a 
result, other collection techniques were explored. Several devices with a 20 nm pore size 
membrane were designed to collect the nanoparticles. However, in many cases the 
nanoparticle collection was not consistent. To address this, a novel collection device was 
built in which the particles could be aggregated at a defined spot. The sample was placed 
on the top of the membrane and vacuum was applied form the bottom to aspirate the 
nanoprobe sample through the specified area. This method allowed for a consistent 
collection of the nanoprobes to simultaneously obtain very low limits of detection and 
high repeatability, which is desired in assays. Nanoprobe samples (10 µL) were detected 
with less than 10 % coefficient of variation (CV) across a range from nearly 27.4 fM to 
1.7 pM using the collection method. 
 Different assay formats were considered to implement the assay. The competitive 
binding assay and the sandwich assay were the most promising formats. These formats 
could also be designed in different versions. A model was created to predict the response 
of a competitive binding sequential displacement assay. Results from the model indicated 
that the response difference between the minimal and maximum expected cTnI 
concentrations was minimal. Additional analysis on the dissociation rate constants of the 
cTnI antibodies suggested that the sequential saturation version of the competitive binding 
assay format would be the best option for this assay. When comparing the sequential 
saturation with the sandwich assay, the sandwich assay was selected because it is known 
to be more sensitive and selective.  
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After synthesizing the nanoprobe, functionalizing the magnetic particles, creating 
the collection device, and selecting the assay format, the assay was tested. Blank samples 
were compared with cTnI samples to determine the assay response. Initial tests indicated 
the presence of nonspecific binding. To address this, different methods such as adding 
more BSA and using streptavidin and neutravidin to conjugate the antibodies on the 
nanoprobe and magnetic particles respectively were implemented. After introducing these 
changes, the assay response that was expected was observed. However, the performance 
of the assay was not optimal. Optimization experiments indicated that the composition of 
the dilution buffer, specifically the addition of BSA or other similar protein to the buffer, 
was essential to reduce nonspecific binding. After optimizing the dilution buffer, clear 
improvements in the signal differences between the analyzed concentrations could be 
distinguished. A concentration curve was measured using the optimized parameters, and 
the expected trend was observed in the test. The curve implies that the dynamic range of 
the assay occurs from 0.5 to 1 ng/mL. This means that the assay sensitivity needs to be 
improved to obtain the ideal dynamic range that spans from 0.01 to 1 ng/mL. 
The final assay results suggest that more optimization is need to be able to measure 
the required low concentrations of cTnI (0.01 ng/mL) with high precision (less than 10% 
CV). Variables such as amount of antibody labeled, amount of components used, assay 
conditions, and buffers used can have a significant impact in the results. Therefore, each 
of them needs to be controlled and optimized. 
The results presented in this work demonstrate the proof of concept of a SERS-
based assay to detect cardiac biomarkers. This assay can be modified to detect other 
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analytes. In addition, once it is optimized, it can be implemented on a microfluidic chip to 
develop a POC device.  
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